US20040116328A1 - Condensed imidazole derivatives - Google Patents

Condensed imidazole derivatives Download PDF

Info

Publication number
US20040116328A1
US20040116328A1 US10/457,002 US45700203A US2004116328A1 US 20040116328 A1 US20040116328 A1 US 20040116328A1 US 45700203 A US45700203 A US 45700203A US 2004116328 A1 US2004116328 A1 US 2004116328A1
Authority
US
United States
Prior art keywords
group
formula
compound
represented
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/457,002
Other languages
English (en)
Inventor
Seiji Yoshikawa
Eita Emori
Fumiyoshi Matsuura
Richard Clark
Hironori Ikuta
Kazunobu Kira
Nobuyuki Yasuda
Tadashi Nagakura
Kazuto Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Assigned to EISAI CO., LTD. reassignment EISAI CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CLARK, RICHARD, EMORI, EITA, IKUTA, HIRONORI, KIRA, KAZUNOBU, MATSUURA, FUMIYOSHI, NAGAKURA, TADASHI, YAMAZAKI, KAZUTO, YASUDA, NOBUYUKI, YOSHIKAWA, SEIJI
Assigned to EISAI CO., LTD. reassignment EISAI CO., LTD. CORRECTION OF ASSIGNEE ADDRESS ON NOTICE OF RECORDATION FOR ASSIGNMENT RECORDED 10/31/03 AT REEL/FRAME 014099/0045 Assignors: CLARK, RICHARD, EMORI, EITA, IKUTA, HIRONORI, KIRA, KAZUNOBU, MATSUURA, FUMIYOSHI, NAGAKURA, TADASHI, YAMAZAKI, KAZUTO, YASUDA, NOBUYUKI, YOSHIKAWA, SEIJI
Publication of US20040116328A1 publication Critical patent/US20040116328A1/en
Priority to US11/212,407 priority Critical patent/US20060063787A1/en
Priority to US12/199,982 priority patent/US7772226B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Definitions

  • the present invention relates to novel condensed imidazole derivatives useful as dipeptidyl peptidase-IV (DPPIV) inhibitors and uses thereof.
  • DPPIV dipeptidyl peptidase-IV
  • Glucose-dependent, insulin secretion-stimulating hormones known as incretins (GLP-1: Glucagon-Like Peptide-1 and GIP: Glucose-dependent Insulinotropic Polypeptide) secreted in the digestive tract following meals are rapidly hydrolyzed and inactivated by DPPIV.
  • DPPIV Glucose-dependent Insulinotropic Polypeptide
  • GLP-1 and GIP Glucose-dependent Insulinotropic Polypeptide
  • GLP-1 is known to be involved in the suppression of appetite and food intake. GLP-1 has also been reported to have the effect of protecting the ⁇ cells of the pancreas by enhancing cell differentiation and proliferation.
  • a DPPIV inhibitor can be a useful therapeutic or preventive agent for diseases with which GLP-1 and/or GIP are associated, such as obesity and diabetes mellitus.
  • a DPPIV inhibitor can be a therapeutic agent for diseases such as:
  • DPPIV inhibitors are disclosed in the Publication of U.S. Pat. No. 2002/0161001; International Publication WO 03/004496; and Publication of U.S. Pat. No. 2002/0198205. However, there is no known DPPIV inhibitor having a hypoxanthine or imidazopyridazinone structure backbone.
  • a compound having DPPIV-inhibiting activity that can be used as a pharmaceutical agent is being anxiously sought as described above.
  • a compound with excellent DPPIV-inhibiting activity which is also highly useful as a clinically effective pharmaceutical is yet to be discovered.
  • an objective of the present invention is to provide compounds having DPPIV-inhibiting activity, which can be used as preventive, therapeutic, or alleviating agents for diabetes mellitus or such diseases.
  • the present inventors conducted extensive studies in view of the above background. As a result, they succeeded in synthesizing novel condensed imidazole derivatives, including hypoxanthine and imidazopyridazinone derivatives. To complete the present invention they also found that these compounds had excellent DPPIV-inhibiting activity. Specifically, the present invention comprises:
  • T 1 represents a monocyclic or bicyclic 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, that may have one or more substituents;
  • X represents a C 1-6 alkyl group which may have one or more substituents, a C 2-6 alkenyl group which may have one or more substituents, a C 2-6 alkynyl group which may have one or more substituents, a C 6-10 aryl group which may have one or more substituents, a 5 to 10-membered heteroaryl group which may have one or more substituents, a C 6-10 aryl C 1-6 alkyl group which may have one or more substituents, or a 5 to 10-membered heteroaryl C 1-6 alkyl group which may have one or more substituents;
  • Z 1 and Z 2 each independently represent a nitrogen atom or a group represented by the formula —CR 2 ⁇ ;
  • R 1 and R 2 each independently represent a group according to the formula -A 0 -A 1 -A 2
  • a 0 represents a single bond or a C 1-6 alkylene group, which may have 1 to 3 substituents selected from group B consisting of the substituents described below;
  • a 1 represents a single bond, an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a group represented by the formula —O—CO—, a group represented by the formula —CO—O—, a group represented by the formula —NR A —, a group represented by the formula —CO—NR A —, a group represented by the formula —NR A —CO—, a group represented by the formula —SO 2 —NR A —, or a group represented by the formula —NR A —SO 2 —;
  • a 2 and R A each independently represent a hydrogen atom, a halogen atom, a cyano group, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, C 6-10 aryl group, a 5 to 10-membered heteroaryl group, a 4 to 8-membered heterocyclic group, a 5 to 10-membered heteroaryl C 1-6 alkyl group, a C 6-10 aryl C 1-6 alkyl group, or a C 2-7 alkylcarbonyl group;
  • a 2 and R A each independently may have 1 to 3 substituents selected from the substituent group B described below:
  • Z 2 is a group represented by the formula —CR 2 ⁇ , R 1 , and R 2 may in combination form a 5 to 7-membered ring;
  • R 1 is a hydrogen atom
  • Z 1 is a nitrogen atom
  • Z 2 is —CH ⁇
  • Z 1 is a nitrogen atom
  • Z 2 is —C(OH) ⁇
  • Substituent group B represents the group consisting of: a hydroxyl group, a mercapto group, a cyano group, a nitro group, a halogen atom, a trifluoromethyl group, a C 1-6 alkyl group which may have one or more substituents, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5 to 10-membered heteroaryl group, a 4 to 8-membered heterocyclic group, a C 1-6 alkoxy group, a C 1-6 alkylthio group, a group represented by the formula —SO 2 —NR B1 —R B2 , a group represented by the formula —NR B1 —CO—R B2 , a group represented by the formula —NR B1 —R B2 (where R B1 and R B2 each independently represent a hydrogen atom
  • n and m each independently represent 0 or 1) which may have one or more substituents
  • an azepan-1-yl group which may have one or more substituents
  • n and m each independently represent 0 or 1
  • an azetidin-1-yl group which may have an amino group
  • a pyrrolidin-1-yl group which may have an amino group
  • an azepan-1-yl group which may have an amino group
  • the phenyl group that may have one or more substituents is a phenyl group which may have at the 2-position a substituent selected from the group consisting of a hydroxyl group, a fluorine atom, a chlorine atom, a methyl group, an ethyl group, a fluoromethyl group, a vinyl group, a methoxy group, an ethoxy group, an acetyl group, a cyano group, a formyl group, and a C 2-7 alkoxycarbonyl group;
  • Z 1 is a nitrogen atom
  • Z 2 is a group represented by the formula —CR 2 ⁇
  • Z 2 is a nitrogen atom
  • Z 1 is a group represented by the formula —CR 2 ⁇
  • R 1 represents a hydrogen atom, or a group represented by the formula -A 10 -A 11 -A 12
  • a 10 represents a C 1-6 alkylene group which may have 1 to 3 substituents selected from the substituent group C described below;
  • a 11 represents a single bond, an oxygen atom, a sulfur atom or a carbonyl group
  • a 12 represents a hydrogen atom, a C 6-10 aryl group which may have 1 to 3 substituents selected from the substituent group C described below, a 5 to 10-membered heteroaryl group which may have 1 to 3 substituents selected from the substituent group C described below, a 5 to 10-membered heteroaryl C 1-6 alkyl group which may have 1 to 3 substituents selected from the substituent group C described below, or a C 6-10 aryl C 1-6 alkyl group which may have 1 to 3 substituents selected from the substituent group C described below:
  • Substituent group C represents the group consisting of: a hydroxyl group, a nitro group, a cyano group, a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkylthio group, a trifluoromethyl group, a group represented by the formula —NR C1 —R C2 (where each of R C1 and R C2 independently represent a hydrogen atom or C 1-6 alkyl group), a group represented by the formula —CO—R C3 —R C4 and a group represented by the formula —CH 2 —CO—R C3 —R C4 (where R C3 represents a single bond, an oxygen atom, or a group represented by the formula —NR C5 —; R C4 and R C5 each independently represent a hydrogen atom or a C 1-6 alkyl group));
  • R 1 is a hydrogen atom, a C 1-6 alkyl group which may have 1 to 3 substituents selected from the substituent group C described below, a 5 to 10-membered heteroaryl C 1-6 alkyl group which may have 1 to 3 substituents selected from the substituent group C described below, or a C 6-10 aryl C 1-6 alkyl group which may have 1 to 3 substituents selected from the substituent group C described below:
  • Substituent group C represents the group consisting of: a hydroxyl group, a nitro group, a cyano group, a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkylthio group, a trifluoromethyl group, a group represented by the formula —NR C1 —R C2 (where each of R C1 and R C2 independently represents a hydrogen atom or a C 1-6 alkyl group), a group represented by the formula —CO—R C3 —R C4 and a group represented by the formula —CH 2 —CO—R C3 —R C4 (where R C3 represents a single bond, an oxygen atom, or a group represented by the formula —NR C5 —; R C4 and R C5 each independently represent a hydrogen atom or a C 1-6 alkyl group);
  • [0074] [17] the compound according to any one of [1] to [13], or a salt or hydrate thereof, wherein R 1 is a methyl group, a cyanobenzyl group, a fluorocyanobenzyl group, a phenethyl group, a 2-methoxyethyl group, or a 4-methoxycarbonylpyridin-2-yl group;
  • R 2 is a hydrogen atom, a cyano group, or a group represented by the formula -A 21 -A 22
  • a 21 represents a single bond, an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a group represented by the formula —O—CO—, a group represented by the formula —CO—O—, a group represented by the formula —NR A2 —, a group represented by the formula —CO—NR A2 —, or a group represented by the formula —NR A2 —CO—;
  • a 22 and R A2 each independently represent a hydrogen atom, a cyano group, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group;
  • a 22 and R A2 each may independently have 1 to 3 substituents selected from the substituent group D described below:
  • Substituent group D represents the group consisting of: a hydroxyl group, a cyano group, a nitro group, a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkylthio group, a trifluoromethyl group, a group represented by the formula —NR D1 —R D2 (where R D1 and R D2 each independently represent a hydrogen atom or a C 1-6 alkyl group), a group represented by the formula —CO—R D3 (where R D3 represents a 4 to 8-membered heterocyclic group), and a group represented by the formula —CO—R D4 —R D5 (where R D4 represents a single bond, an oxygen atom, or a group represented by the formula —NR D6 —; R D5 and R D6 each independently represent a hydrogen atom, a C 3-8 cycloalkyl group, or a C 1-6 alky
  • R 2 represents a hydrogen atom, a cyano group, a carboxy group, a C 2-7 alkoxycarbonyl group, a C 1-6 alkyl group, a group represented by the formula —CONR D7 R D8 (where R D7 and R D8 each independently represent a hydrogen atom or a C 1-6 alkyl group), or a group represented by the formula -A 23 -A 24
  • a 23 represents an oxygen atom, a sulfur atom or a group represented by the formula —NR A3 —;
  • a 24 and R A3 each independently represent a hydrogen atom, a C 1-6 alkyl group which may have a substituent selected from the substituent group D1 described below, a C 3-8 cycloalkyl group which may have a substituent selected from the substituent group D1 described below, a C 2-6 alkenyl group which may have a substituent selected from the substituent group D1 described below, a C 2-6 alkynyl group which may have a substituent selected from the substituent group D1 described below, a phenyl group which may have a substituent selected from the substituent group D1 described below, or a 5 to 10-membered heteroaryl group which may have a substituent selected from the substituent group D1 described below:
  • Substituent group D1 represents the group consisting of: a carboxy group, a C 2-7 alkoxycarbonyl group, a C 1-6 alkyl group, a group represented by the formula —CONR D7 R D8 (where R D7 and R D8 each independently represent a hydrogen atom or C 1-6 alkyl group), a pyrrolidin-1-ylcarbonyl group, a C 1-6 alkyl group, and a C 1-6 alkoxy group);
  • R 2 represents a hydrogen atom, a cyano group, a C 1-6 alkoxy group, or a group represented by the formula -A 25 -A 26
  • a 25 represents an oxygen atom, a sulfur atom, or a group represented by the formula —NR A4 —;
  • a 26 and R A4 each independently represent a hydrogen atom, a C 1-6 alkyl group having a substituent selected from the substituent group D1 described below, a C 3-8 cycloalkyl group having a substituent selected from the substituent group D1 described below, or a phenyl group having a substituent selected from the substituent group D1 described below:
  • Substituent group D1 represents the group consisting of: a carboxy group, a C 2-7 alkoxycarbonyl group, a C 1-6 alkyl group, a group represented by the formula —CONR D7 R D8 (where R D7 and R D8 each independently represent a hydrogen atom or a C 1-6 alkyl group), pyrrolidin-1-ylcarbonyl group, a C 1-6 alkyl group, and a C 1-6 alkoxy group);
  • R 2 is a hydrogen atom, a cyano group, a methoxy group, a carbamoylphenyloxy group, or a group represented by the following formula:
  • a 27 represents an oxygen atom, a sulfur atom, or —NH—;
  • a 28 and A 29 each independently represent a hydrogen atom or a C 1-6 alkyl group);
  • a preventive or a therapeutic agent for diabetes mellitus which comprises a compound of any one of [1] to [24];
  • a preventive or therapeutic agent which comprises a compound of any one of [1] to [24], for diabetes mellitus, obesity, hyperlipidemia, AIDS, osteoporosis, a gastrointestinal disorder, angiogenesis, infertility, an inflammatory disease, an allergic disease, or cancer;
  • an immunomodulator a hormone modulator, or an anti-rheumatic drug, which comprises a compound of any one of [1] to [24];
  • [0115] a therapeutic or preventive method for a disease in which the inhibition of dipeptidyl peptidase IV is effective, wherein the method comprises administering to a patient a compound of any one of [1] to [24], or a salt or hydrate thereof, in a pharmaceutically effective amount;
  • T 0 represents,
  • n and m each independently represent 0 or 1
  • substituents represented by the following formula:
  • X 0 represents a C 3-8 cycloalkyl group which may have one or more substituents, a C 1-6 alkyl group which may have one or more substituents, a C 2-6 alkenyl group which may have one or more substituents, a C 2-6 alkynyl group which may have one or more substituents, a C 6-10 aryl group which may have one or more substituents, a 5 to 10-membered heteroaryl group which may have one or more substituents, a C 6-10 aryl C 1-6 alkyl group which may have one or more substituents, or a 5 to 10-membered heteroaryl C 1-6 alkyl group which may have one or more substituents; and
  • R 1 , Z 1 and Z 2 are, as defined above in [1];
  • R 1 , R 2 , T 1 , Z 1 and Z 2 are, as defined above in [1];
  • R 1 , R 2 , T 1 , Z 1 and Z 2 are, as defined above in [1];
  • R 1 is as defined above in [1]
  • R p5 represents a t-butoxycarbonyloxy group, a trityl group or a group represented by the formula —SO 2 NH 2 ;
  • T 10 represents a halogen atom or a hydrogen atom
  • R 1 is as defined above in [1];
  • T 11 represents a halogen atom or a group represented by the following formula:
  • T 13 represents a t-butoxycarbonyl group, a benzyloxycarbonyl group, or a formyl group
  • R 1 and X are as defined above in [1], respectively;
  • T 12 represents a halogen atom
  • X is as defined above in [1], except when X is a benzyl group;
  • T21 and T22 each independently represent a halogen atom
  • T 11 represents a halogen atom or a group represented by the following formula:
  • T 13 represents a t-butoxycarbonyl group, a benzyloxycarbonyl group, or a formyl group
  • X and R 1 are as defined above in [1], respectively;
  • T 22 represents a halogen atom
  • T 13 represents a t-butoxycarbonyl group, a benzyloxycarbonyl group, or a formyl group;
  • the ring of T 1 represents a monocyclic or bicyclic 6- to 12-membered heterocyclic group containing two nitrogen atoms in the ring, which may have one or more substituents;
  • X represents a C 1-6 alkyl group which may have one or more substituents, a C 2-6 alkenyl group which may have one or more substituents, a C 2-6 alkynyl group which may have one or more substituents, a C 6-10 aryl group which may have one or more substituents, a 5 to 10-membered heteroaryl group which may have one or more substituents, a C 6-10 aryl C 1-6 alkyl group which may have one or more substituents, or a 5 to 10-membered heteroaryl C 1-6 alkyl group which may have one or more substituents;
  • X may form a bond with an atom constituting the ring of T 1 ;
  • Z 1 and Z 2 each independently represent a nitrogen atom or a group represented by the formula —CR 2 ⁇ ;
  • R 1 and R 2 independently represent a hydrogen atom, a 4- to 8-membered heterocyclic group which may have one or more substituents, or a group represented by the formula -A 0 -A 1 -A 2
  • a 0 represents a single bond or a C 1-6 alkylene group that may have 1 to 3 substituents selected from the substituent group B described below;
  • A1 represents a single bond, an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a group represented by the formula —O—CO—, a group represented by the formula —CO—O—, a group represented by the formula —NR A —, a group represented by the formula —CO—NR A —, a group represented by the formula —NR A —CO—, a group represented by the formula —SO 2 —NR A —, or a group represented by the formula —NR A —SO 2 —;
  • a 2 and R A each independently represent a hydrogen atom, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5 to 10-membered heteroaryl group, or a 4 to 8-membered heterocyclic group.
  • a 2 and R A each may independently have 1 to 3 substituents selected from the substituent group B described below:
  • Substituent group B represents the group consisting of: a hydroxyl group, a cyano group, a halogen atom, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5 to 10-membered heteroaryl group, a 4 to 8-membered heterocyclic group, a C 1-6 alkoky group, a C 1-6 alkylthio group, and a group represented by the formula —CO—R B —R B2 (where R B represents a single bond, an oxygen atom, or a group represented by the formula —NR B3 —; R B2 and R B3 each independently represent a hydrogen atom, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkyny
  • a structural formula of a compound sometimes represents a certain isomer for convenience of description.
  • compounds of the present invention may include all possible isomers, such as structurally possible geometric isomers, optical isomers generated due to the presence of asymmetric carbons, stereoisomers, tautomers, and mixtures of isomers, and are not limited to formulae being used for the convenience of description, and may be either of two isomers or a mixture of both isomers.
  • compounds of the present invention may be either optically active compounds having an asymmetric carbon atom in their molecules or their racemates, and are not restricted to either of them but include both.
  • compounds of the present invention may exhibit crystalline polymorphism, but likewise are not restricted to any one of these but may be in any one of these crystal forms or exist as a mixture of two or more crystal forms.
  • Compounds of the present invention also include both anhydrous and hydrated forms. Substances produced through in vivo metabolism of compounds of the invention are also within the scope of claims.
  • C 1-6 alkyl group refers to a linear or branched alkyl group containing 1 to 6 carbon atoms, which is a monovalent group obtained by removal of any one of the hydrogen atoms from an aliphatic hydrocarbon containing 1 to 6 carbons, and specifically, includes, for example, a methyl group, an ethyl group, a 1-propyl group, a 2-propyl group, a 2-methyl-1-propyl group, a 2-methyl-2-propyl group, a 1-butyl group, a 2-butyl group, a 1-pentyl group, a 2-pentyl group, a 3-pentyl group, a 2-methyl-1-butyl group, a 3-methyl-1-butyl group, a 2-methyl-2-butyl group, a 3-methyl-2-butyl group, a 2,2-dimethyl-1-propyl group, a 1-hexyl group, a 2-hexy
  • C 2-6 alkenyl group refers to a linear or branched alkenyl group containing 2 to 6 carbons, and specifically includes, for example, a vinyl group, an allyl group, a 1-propenyl group, a 2-propenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a pentenyl group, and a hexenyl group.
  • C 2-6 alkynyl group refers to a linear or branched alkynyl group containing 2 to 6 carbons, and specifically includes, for example, an ethynyl group, a 1-propynyl group, a 2-propynyl group, a butynyl group, a pentynyl group, and a hexynyl group.
  • C 3-8 cycloalkyl group refers to a cyclic aliphatic hydrocarbon group containing 3 to 8 carbon atoms, and specifically includes, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, and a cyclooctyl group.
  • C 1-6 alkylene group refers to a divalent group obtained by removal of another arbitrary hydrogen atom from a “C 1-6 alkyl group” defined above, and specifically includes, for example, a methylene group, a 1,2-ethylene group, a 1,1-ethylene group, a 1,3-propylene group, a tetramethylene group, a pentamethylene group, and a hexamethylene group.
  • C 3-8 cycloalkylene group refers to a divalent group obtained by removal of another arbitrary hydrogen atom from a “C 3-8 cycloalkyl group” defined above.
  • C 1-6 alkoxy group refers to an oxy group linked to a “C 1-6 alkyl group” defined above, and specifically includes, for example, a methoxy group, an ethoxy group, a 1-propyloxy group, a 2-propyloxy group, a 2-methyl-1-propyloxy group, a 2-methyl-2-propyloxy group, a 1-butyloxy group, a 2-butyloxy group, a 1-pentyloxy group, a 2-pentyloxy group, a 3-pentyloxy group, a 2-methyl-1-butyloxy group, a 3-methyl-1-butyloxy group, a 2-methyl-2-butyloxy group, a 3-methyl-2-butyloxy group, a 2,2-dimethyl-1-propyloxy group , a 1-hexyloxy group, a 2-hexyloxy group, a 3-hexyloxy group, a 2-methyl-1-p
  • C 1-6 alkylthio group refers to a thio group linked to a “C 1-6 alkyl group” defined above, and specifically includes, for example, a methylthio group, an ethylthio group, a 1-propylthio group, a 2-propylthio group, a butylthio group, and a pentylthio group.
  • C 2-7 alkoxycarbonyl group refers to a carbonyl group linked to a “C 1-6 alkoxy group” defined above, and specifically includes, for example, a methoxycarbonyl group, an ethoxycarbonyl group, a 1-propyloxycarbonyl group, and a 2-propyloxycarbonyl group.
  • C 2-7 alkylcarbonyl group refers to a carbonyl group linked to a “C 1-6 alkyl group” defined above, and specifically includes, for example, a methylcarbonyl group, an ethylcarbonyl group, a 1-propylcarbonyl group, and a 2-propylcarbonyl group.
  • halogen atom refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
  • C 6-10 aryl group refers to an aromatic cyclic hydrocarbon group containing 6 to 10 carbon atoms, and specifically includes, for example, a phenyl group, a 1-naphthyl group, and a 2-naphthyl group.
  • heteroatom refers to a sulfur atom, an oxygen atom, or a nitrogen atom.
  • the phrase “5 to 10-membered heteroaryl ring” refers to an aromatic 5 to 10-membered ring containing one or more heteroatoms, and specifically includes, for example, a pyridine ring, a thiophene ring, a furan ring, a pyrrole ring, an oxazole ring, an isoxazole ring, a thiazole ring, a thiadiazole ring, an isothiazole ring, an imidazole ring, a triazole ring, a pyrazole ring, a furazan ring, a thiadiazole ring, an oxadiazole ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, indole ring, an isoindole ring, an indazole ring, a chromen
  • Preferable “5 to 10-membered heteroaryl rings” include a pyridine ring, a thiophene ring, a furan ring, a pyrrole ring, an imidazole ring, a 1,2,4-triazole ring, a thiazole ring, a thiadiazole ring, a pyrazole ring, a furazan ring, a thiadiazole ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, an isoquinoline ring, a benzoxazole ring, a benzothiazole ring, and a benzimidazole ring.
  • the most preferable example is a pyridine ring.
  • the phrase “5 to 10-membered heteroaryl group” refers to a monovalent or divalent group obtained by removal of any one or two hydrogen atoms from a “5 to 10-membered heteroaryl ring” described above.
  • the atoms constituting the ring include 1 to 2 heteroatoms
  • the ring may contain 1 to 2 double bonds
  • the ring may contain 1 to 3 carbonyl groups
  • the 4 to 8-membered heterocyclic ring includes, for example, an azetidine ring, a pyrrolidine ring, a piperidine ring, an azepan ring, an azocane ring, a tetrahydrofuran ring, a tetrahydropyran ring, a morpholine ring, a thiomorpholine ring, a piperazine ring, a thiazolidine ring, a dioxane ring, an imidazoline ring, a thiazoline ring, and a ring represented by one of the formulae:
  • T 3x represents a methylene group, an oxygen atom or a group represented by the formula —NT 4x -, wherein T 4x represents a hydrogen atom or C 1-6 alkyl group.
  • the “4- to 8-membered heterocyclic rings” include a pyrrolidine ring, a piperidine ring, an azepan ring, a morpholine ring, a thiomorpholine ring, a piperazine ring, a dihydrofuran-2-one ring, and a thiazolidine ring.
  • the phrase “4 to 8-membered heterocyclic group” refers to a monovalent or divalent group obtained by removal of any one or two hydrogen atoms from a “4 to 8-membered heterocycle” described above.
  • the “4 to 8-membered heterocyclic groups” include a piperidin-1-yl group, a pyrrolidin-1-yl group, and a morpholin-4-yl group.
  • C 6-10 aryl C 1-6 alkyl group refers to a group obtained by substitution of a “C 6-10 aryl group” defined above for an arbitrary hydrogen atom in a “C 1-6 alkyl group” defined above, and specifically includes, for example, a benzyl group, a phenethyl group, and a 3-phenyl-1-propyl group.
  • the phrase “5 to 10-membered heteroaryl C 1-6 alkyl group” refers to a group obtained by substitution of a “5 to 10-membered heteroaryl group” defined above for an arbitrary hydrogen atom in a “C 1-6 alkyl group” defined above, and specifically, includes for example, a 2-pyridylmethyl and a 2-thienylmethyl group.
  • the phrase “4 to 8-membered heterocyclic C 1-6 alkyl group” refers to a group obtained by substitution of a “4 to 8-membered heterocyclic group” defined above for an arbitrary hydrogen atom in a “C 1-6 alkyl group” defined above.
  • the phrase “monocyclic or bicyclic 4 to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, that may have one or more substituents” refers to a non-aromatic cyclic group which may have one or more substituents.
  • the non-aromatic cyclic groups :
  • the atoms constituting the ring of the cyclic group include one or two nitrogen atoms;
  • the group is a monocyclic or bicyclic structure.
  • n and m each independently represent 0 or 1; R 31 to R 44 independently represent a hydrogen atom or a substituent selected from substituents referred to in the phrase “which may have one or more substituents” (the substituent group S defined below); any two of R 31 to R 44 may in combination form a C 1-6 alkylene group).
  • substituents means that a group may have one or more substituents in any combination at replaceable positions.
  • substituents include, for example, a substituent selected from the substituent group S defined below.
  • This group consists of:
  • T 1x is a single bond, a C 1-6 alkylene group, an oxygen atom, a group represented by the formula —CO—, a group represented by the formula —S—, a group represented by the formula —S(O)—, a group represented by the formula —S(O) 2 —, a group represented by the formula —O—CO—, a group represented by the formula —CO—O—, a group represented by the formula —NR T —, a group represented by the formula —CO—NR T —, a group represented by the formula —NR T —CO—, a group represented by the formula —SO 2 —NR T —, a group represented by the formula —NR T —SO 2 —, a group represented by the formula —NH—CO—NR T — or a group represented by the formula —NH—CS—NR T —;
  • T 2x represents a hydrogen atom, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a phenyl group, a 1-naphthyl group, a 2-naphthyl group, a 5 to 10-membered heteroaryl group or a 4 to 8-membered heterocyclic group;
  • R T represents a hydrogen atom, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group or a C 2-6 alkynyl group;
  • T 2x and R T each may independently have 1 to 3 substituents selected from the substituent group T defined below).
  • This group consists of: hydroxyl, cyano, a halogen atom, C 1-6 alkyl, C 3-8 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, 1-naphthyl, 2-naphthyl, 5 to 10-membered heteroaryl, 4 to 8-membered heterocyclic ring, C 1-6 alkoxy, C 1-6 alkylthio, C 2-7 alkoxycarbonyl group, etc.
  • the ⁇ substituent group S> preferably consists of:
  • n and m each independently represent 0 or 1
  • substituents refers to a group represented by the formula:
  • R 31 , R 32 , R 33 , R 34 , and R 35 independently represent a hydrogen atom or a group selected from substituent groups referred to in the phrase “which may have one or more substituents” (the substituent group S defined above)); provided that, at least three of R 31 , R 32 , R 33 , R 34 , and R 35 are hydrogen atoms Still more preferably, the term refers to a group represented by one of the formulae:
  • piperidin-1-yl group which may have one or more substituents refers to a “piperidin-1-yl group” which may have one or more substituents selected from the groups referred to in the phrase “which may have one or more substituents” (the substituent group S defined above) at replaceable positions.
  • the “piperidin-1-yl group which may have one or more substituents” refers to a group represented by the formula:
  • R 31 , R 32 , R 33 , R 34 and R 35 each independently represent a hydrogen atom or a group selected from the substituents referred to in the phrase “which may have one or more substituents” (the substituent group S defined above)); provided that, at least three of R 31 , R 32 , R 33 , R 34 , and R 35 are hydrogen atoms.
  • the term refers to a group represented by one of the formulae:
  • the term refers to a group represented by one of the formulae:
  • azetidin-1-yl group may have one or more substituents” refers to an “azetidin-1-yl group” which may have one or more groups selected from the substituents referred to in the phrase “which may have one or more substituents” at replaceable positions.
  • pyrrolidin-1-yl group may have one or more substituents” refers to a “pyrrolidin-1-yl group” which may have one or more groups selected from the substituents referred to in the phrase “which may have one or more substituents” at replaceable positions.
  • piperidin-1-yl group may have one or more substituents” refers to a “piperidin-1-yl group” which may have one or more groups selected from the substituents referred to in the phrase “which may have one or more substituents” at replaceable positions.
  • azepan-1-yl group may have one or more substituents” refers to an “azepan-1-yl group” which may have one or more groups selected from the substituents referred to in the phrase “which may have one or more substituents” at replaceable positions.
  • piperidin-1-yl group which may have an amino group refers to a “piperidin-1-yl group” which may have an amino group at a replaceable position.
  • the “piperidin-1-yl group which may have an amino group” refers to the group represented by one of the formulae:
  • azetidin-1-yl group which may have an amino group refers to an “azetidin-1-yl group” which may have an amino group at a replaceable position.
  • pyrrolidin-1-yl group which may have an amino group refers to a “pyrrolidin-1-yl group” which may have an amino group at a replaceable position.
  • piperidin-1-yl group which may have an amino group refers to a “piperidin-1-yl group” which may have an amino group at a replaceable position.
  • azepan-1-yl group which may have an amino group refers to an “azepan-1-yl group” which may have an amino group at a replaceable position.
  • C 1-6 alkyl group which may have one or more substituents in the substituent group B defined above refers to a “C 1-6 alkyl group” which may have one or more groups selected from the substituents referred to in the phrase “which may have one or more substituents” at replaceable positions.
  • the “C 1-6 alkyl group which may have one or more substituents” refers to a C 1-6 alkyl group which may have one or two substituents selected from the group consisting of a cyano group, a carboxyl group, a C 2-7 alkoxycarbonyl group, a group represented by the formula —NR 3T COR 4T , a group represented by the formula —CONR 3T R 4T (where R 3T and R 4T each independently represent a hydrogen atom or a C 1-6 alkyl group), and a C 1-6 alkoxy group.
  • R 1 and R 2 each independently represent a group of the formula -A 0 -A 1 -A 2 (where A 0 , A 1 , and A 2 are as defined above); when both A 0 and A 1 are single bonds, “-A 0 -A 1 -” represents a single bond.
  • a T1 represents an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a methylene group which may have one or more substituents, or a nitrogen atom which may have one or more substituents;
  • a T2 represents a C 2-6 alkylene group which may have one or more substituents).
  • a T1 preferably represents an oxygen atom
  • a T2 preferably represents a C 2-4 alkylene group.
  • cyanobenzyl group refers to a benzyl group having one cyano group, and specifically, includes, for example, a 2-cyanobenzyl group, a 3-cyanobenzyl group, and a 4-cyanobenzyl group.
  • fluorocyanobenzyl group refers to a benzyl group having one fluorine atom and one cyano group, and specifically, includes, for example, a 2-cyano-4-fluorobenzyl group and a 2-cyano-6-fluorobenzyl group.
  • carbamoylphenoxy group refers to a phenoxy group having a group represented by the formula —CONH 2 , and specifically, includes, for example, a 2-carbamoylphenoxy group, a 3-carbamoylphenoxy group, and a 4-carbamoylphenoxy group.
  • salts include, for example, inorganic acid salts, organic acid salts, inorganic base salts, organic base salts, and acidic or basic amino acid salts.
  • Examples of preferred inorganic salts include hydrochloride, hydrobromide, sulfate, nitrate, and phosphate.
  • Examples of preferred organic salts include acetate, succinate, fumarate, maleate, tartrate, citrate, lactate, stearate, benzoate, methanesulfonate, and p-toluene sulfonate.
  • Examples of preferred inorganic base salts include: alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; aluminum salts; and ammonium salts.
  • Examples of preferred organic base salts include diethylamine salts, diethanolamine salts, meglumine salts, and N,N′-dibenzylethylenediamine salts.
  • Examples of preferred acidic amino acid salts include aspartate and glutamate.
  • Examples of preferred basic amino acid salts include arginine salts, lysine salts, and ornithine salts.
  • the present invention provides compounds represented by the following formula (I), or salts or hydrates thereof:
  • T 1 represents a monocyclic or bicyclic 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, and may have one or more substituents;
  • X represents a C 1-6 alkyl group which may have one or more substituents, a C 2-6 alkenyl group which may have one or more substituents, a C 2-6 alkynyl group which may have one or more substituents, a C 6-10 aryl group which may have one or more substituents, a 5- to 10-membered heteroaryl group which may have one or more substituents, a C 6-10 aryl C 1-6 alkyl group which may have one or more substituents, or a 5- to 10-membered heteroaryl C 1-6 alkyl group which may have one or more substituents;
  • Z 1 and Z 2 each independently represent a nitrogen atom or a group represented by the formula —CR 2 ⁇ ;
  • R 1 and R 2 each independently represent a group of the formula -A 0 -A 1 -A 2
  • a 0 represents a single bond or a C 1-6 alkylene group which may have 1 to 3 substituents selected from the substituent group B described below;
  • a 1 represents a single bond, an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a group represented by the formula —O—CO—, a group represented by the formula —CO—O—, a group represented by the formula —NR A —, a group represented by the formula —CO—NR A —, a group represented by the formula —NR A —CO—, a group represented by the formula —SO 2 —NR A —, or a group represented by the formula —NR A —SO 2 —;
  • a 2 and R A each independently represent a hydrogen atom, a halogen atom, a cyano group, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5 to 10-membered heteroaryl group, a 4 to 8-membered heterocyclic group, a 5 to 10-membered heteroaryl C 1-6 alkyl group, a C 6-10 aryl C 1-6 alkyl group, or a C 2-7 alkylcarbonyl group, provided that, A2 and R A each may independently have 1 to 3 substituents selected from the substituent group B defined below);
  • R 1 and R 2 may in combination form a 5 to 7-membered ring.
  • the substituent group B represents the group consisting of: a hydroxyl group, a mercapto group, a cyano group, a nitro group, a halogen atom, a trifluoromethyl group, a C 1-6 alkyl group which may have one or more substituents, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5 to 10-membered heteroaryl group, a 4 to 8-membered heterocyclic group, a C 1-6 alkoxy group, a C 1-6 alkylthio group, a group represented by the formula —SO 2 —NR B1 —R B2 , a group represented by the formula —NR B1 —CO—R B2 , a group represented by the formula —NR B1 —R B2 (where R B1 and R B2 each independently represent a hydrogen atom or
  • Preferable compounds represented by the formula (I) include, for example, the following compounds:
  • Z 1 is a nitrogen atom
  • Z 2 is a group represented by the formula —CR 2 ⁇ (where R 2 has the same definition as R 2 defined above);
  • Z 2 is a nitrogen atom
  • Z 1 is a group represented by the formula —CR 2 ⁇ (where R 2 has the same definition as R 2 defined above);
  • T 1 is a group which may have one or more substituents and is represented by the formula:
  • n and m each independently represent 0 or 1), an azetidin-1-yl group which may have one or more substituents, a pyrrolidin-1-yl group which may have one or more substituents, a piperidin-1-yl group which may have one or more substituents, or an azepan-1-yl group which may have one or more substituents;
  • n and m each independently represent 0 or 1), an azetidin-1-yl group which may have an amino group, a pyrrolidin-1-yl group which may have an amino group, a piperidin-1-yl group which may have an amino group, or an azepan-1-yl group which may have an amino group;
  • T 1 is a piperazin-1-yl group or a 3-amino piperidin-1-yl group
  • X is a group represented by the formula —X 1 —X 2 (where X 1 represents a single bond or a methylene group which may have one or more substituents; X 2 represents a C 2-6 alkenyl group which may have one or more substituents, a C 2-6 alkynyl group may have one or more substituents, or a phenyl group which may have one or more substituents);
  • the phenyl group, which may have one or more substituents, of X represented by the group of the above formula —X 11 —X 12 is a phenyl group which may have, at the 2 position, a substituent selected from the group consisting of: a hydroxyl group, a fluorine atom, a chlorine atom, a methyl group, a ethyl group, a fluoromethyl group, a vinyl group, a methoxy group, an ethoxy group, an acetyl group, a cyano group, a formyl group, and a C 2-7 alkoxycarbonyl group;
  • a 10 represents a C 1-6 alkylene group which may have 1 to 3 substituents selected from the substituent group C described below;
  • a 11 represents a single bond, an oxygen atom, a sulfur atom, or a carbonyl group
  • a 12 represents a hydrogen atom, a C 6-10 aryl group which may have 1 to 3 substituents selected from the substituent group C described below, a 5 to 10-membered heteroaryl group which may have 1 to 3 substituents selected from the substituent group C described below, a 5 to 10-membered heteroaryl C 1-6 alkyl group which may have 1 to 3 substituents selected from the substituent group C described below, or a C 6-10 aryl C 1-6 alkyl group which may have 1 to 3 substituents selected from the substituent group C described below;
  • the substituent group C represents the group consisting of: a hydroxyl group, a nitro group, a cyano group, a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkylthio group, a trifluoromethyl group, a group represented by the formula —NR C1 —R C2 , (where each of R C1 and R C2 independently represent a hydrogen atom or a C 1-6 alkyl group), a group represented by the formula —CO—R C3 —R C4 and a group represented by the formula —CH 2 —CO—R C3 —R C4 (where R C3 represents a single bond, an oxygen atom or a group represented by the formula —NR C5 —; R C4 and R C5 each independently represent a hydrogen atom or a C 1-6 alkyl group);
  • R 1 is a hydrogen atom, a C 1-6 alkyl group which may have 1 to 3 substituents selected from the substituent group C described below, a 5 to 10-membered heteroaryl C 1-6 alkyl group which may have 1 to 3 substituents selected from the substituent group C described below, or a C 6-10 aryl C 1-6 alkyl group which may have 1 to 3 substituents selected from the substituent group C described below;
  • the substituent group C represents the group consisting of: a hydroxyl group, a nitro group, a cyano group, a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkylthio group, a trifluoromethyl group, a group represented by the formula —NR C1 —R C2 (where R C1 and R C2 each independently represent a hydrogen atom, or a C 1-6 alkyl group), a group represented by the formula —CO—R C3 —R C4 and a group represented by the formula —CH 2 —CO—R C3 —R C4 (where R C3 represents a single bond, an oxygen atom, or a group represented by the formula —NR C5 —; R C4 and R C5 each independently represent a hydrogen atom or a C 1-6 alkyl group);
  • R 1 is a methyl group, a cyanobenzyl group, a fluorocyanobenzyl group, a phenethyl group, a 2-methoxyethyl group or a 4-methoxycarbonyl-pyridin-2-yl group;
  • a 21 represents a single bond, an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a group represented by the formula —O—CO—, a group represented by the formula —CO—O—, a group represented by the formula —NR A2 —, a group represented by the formula —CO—NR A2 —, or a group represented by the formula —NR A2 —CO—;
  • a 22 and R A2 each independently represent a hydrogen atom, a cyano group, a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5 to 10-membered heteroaryl group, a 4 to 8-membered heterocyclic group, a 5 to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, provided that, A 22 and R A2 each independently may have 1 to 3 substituents selected from the substituent group D described below;
  • the substituent group D represents the group consisting of a hydroxyl group, a cyano group, a nitro group, a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkylthio group, a trifluoromethyl group, a group represented by the formula —NR D1 —R D2 (where R D1 and R D2 each independently represent a hydrogen atom or a C 1-6 alkyl group), a group represented by the formula —CO—R D3 (where R D3 represents a 4 to 8-membered heterocyclic group), and a group represented by the formula —CO—R D4 —R D5 (where R D4 represents a single bond, an oxygen atom, or a group represented by the formula —NR D6 —; R D5 and R D6 each independently represent a hydrogen atom, a C 3-8 cycloalkyl group or a C 1-6 alkyl group);
  • R 2 is a hydrogen atom, a cyano group, a carboxy group, a C 2-7 alkoxycarbonyl group, a C 1-6 alkyl group, a group represented by the formula —CONR D7 R D8 (where R D7 and R D8 each independently represent a hydrogen atom or C 1-6 alkyl group), a group represented by the formula -A 23 -A 24 (where A 23 represents an oxygen atom, a sulfur atom, or a group represented by the formula —NR A3 —; A 24 and R A3 each independently represent a hydrogen atom, a C 1-6 alkyl group which may have a substituent selected from the substituent group D1 described below, a C 3-8 cycloalkyl group which may have a substituent selected from the substituent group D1 described below, a C 2-6 alkenyl group which may have a substituent selected from the substituent group D1 described below, a C 2-6 alkynyl
  • the substituent group D1 represents the group consisting of a carboxy group, a C 2-7 alkoxycarbonyl group, a C 1-6 alkyl group, a group represented by the formula —CONR D7 R D8 (where R D7 and R D8 each independently represent a hydrogen atom or C 1-6 alkyl group), a pyrrolidin-1-ylcarbonyl group, a C 1-6 alkyl group, and a C 1-6 alkoxy group;
  • R 2 is a hydrogen atom, a cyano group, a C 1-6 alkoxy group, or a group of the formula -A 25 -A 26 (where A 25 represents an oxygen atom, a sulfur atom, or a group represented by the formula —NR A4 —; A 26 and R A4 each independently represent a hydrogen atom, a C 1-6 alkyl group having a substituent selected from the substituent group D1 described below, a C 3-8 cycloalkyl group having a substituent selected from the substituent group D1 described below, or a phenyl group having a substituent selected from the substituent group D1 described below);
  • the substituent group D1 represents the group consisting of a carboxyl group, a C 2-7 alkoxycarbonyl group, a C 1-6 alkyl group, a group represented by the formula —CONR D7 R D8 (where R D7 and R D8 each independently represent a hydrogen atom or a C 1-6 alkyl group), a pyrrolidin-1-ylcarbonyl group, a C 1-6 alkyl group, and a C 1-6 alkoxy group;
  • a 27 represents an oxygen atom, a sulfur atom, or a group represented by the formula —NH—;
  • a 28 an A 29 each independently represent a hydrogen atom or a C 1-6 alkyl group
  • R 2 is a hydrogen atom, a cyano group, or a carbamoylphenyloxy group.
  • the order of preference is (1) to (3) with (3) the most preferable; with respect to T 1 , the order of preference is (4) to (7) with (7) the most preferable; with respect to X, the order of preference is (8) to (12) with (12) the most preferable; with respect to R 1 , the order of preference is (13) to (17) with (17) the most preferable; with respect to R 2 , the order of preference is (18) to (22) with (22) the most preferable.
  • preferred compounds represented by above formula (I) include compounds defined by any 2 to 5 embodiments selected from the groups consisting of (1)-(3), (4)-(7), (8)-(12), (13)-(17), and (18)-(22).
  • Preferable compounds include, for example, compounds defined by the following specific combinations of embodiments:
  • R 31 to R 42 , n, m, R 1 , R 2 , X, A 0 , A 1 , A 2 , R A , and T 1 are the same as defined above.
  • U 1 and U 3 each independently represent a leaving group such as a chlorine atom, a bromine atom, an iodine atom, a methanesulfonyloxy group, or a p-toluenesulfonyloxy group.
  • R p1 , R p2 , and R p3 each independently represent an —NH-protecting group such as a pivalyloxymethyl group and a trimethylsilylethoxymethyl group.
  • R p4 represents a hydroxyl group-protecting group such as a t-butyldimethylsilyl group and a t-butyldiphenylsilyl group.
  • R p5 represents an NH-protecting group such as N,N-dimethylsulfamoyl, trityl, benzyl, and t-butoxycarbonyl.
  • U 2 and U 4 each independently represent a chlorine atom, a bromine atom, an iodine atom, a methanesulfonyloxy group, a p-toluenesulfonyloxy group, a group represented by the formula —B(OH) 2 , a 4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl group, or a group represented by the formula —Sn(R z ) 3 (where R z represents a C 1-6 alkyl group).
  • R x2 is a group represented by the formula —O-A 2 , a group represented by the formula —S-A 2 , a group represented by the formula —N(R A )A 2 , or a 4- to 8-membered heterocyclic group which may have one or more substituents (for example, 1-pyrrolidinyl, 1-morpholinyl, 1-piperazinyl, or 1-piperidyl), etc.
  • R x3 represents a group of the formula -A 0 -A 1 -A 2 , such as a cyano group, a C 1-6 alkyl group which may have one or more substituents, a C 3-8 cycloalkyl group which may have one or more substituents, a C 2-6 alkenyl group which may have one or more substituents, a C 2-6 alkynyl group which may have one or more substituents, and a C 6-10 aryl group which may have one or more substituents.
  • a 2COOR represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains an ester group.
  • a 2COOH represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains a carboxylic acid.
  • a 2NO2 represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains a nitro group.
  • a 2NH2 represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains an amino group.
  • a 2CN represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains a nitrile group.
  • a CONH2 represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains a carboxylic amide group.
  • M represents —MgCl, —MgBr, —Sn(R z ) 3 (where R z is as defined above), etc.
  • room temperature refers to a temperature of about 20 to about 30° C.
  • T 1a is defined as the group represented by T 1 , or represents a group of the formula:
  • reaction schemes In examples of reactions represented by the following reaction schemes, unless otherwise specified, quantities of reagents, catalysts, and others, to be used (equivalent, weight %, and weight ratio) are represented as ratios to a main compound in each reaction scheme.
  • a main compound refers to a compound represented by a chemical formula in the reaction scheme and having the backbone of compounds of the present invention.
  • an —NH-protecting reagent is reacted with compound (1a) [CAS No. 56160-64-6] to give compound (2a).
  • the reaction conditions are selected depending on the type of —NH-protecting reagent to be used.
  • the reaction may be performed under conditions that are generally used to introduce a protecting group using the reagent.
  • An —NH-protecting reagent can be a reagent that is generally used to introduce an —NH-protecting group.
  • —NH-protecting reagents include, for example, chloromethyl pivalate. It is preferable to use 1 to 2 equivalents of a protecting reagent.
  • Solvents for the reaction include acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane. N,N-dimethylformamide is preferably used.
  • the reaction can be achieved in the presence of a base.
  • bases to be used in the reaction include cesium carbonate, lithium carbonate, sodium carbonate, potassium carbonate, and sodium hydride.
  • Sodium hydride is preferably used.
  • a base is preferably used in an amount of 1 to 5 equivalents.
  • the reaction can be conducted at a temperature ranging from 0° C. to 150° C. A preferred reaction temperature is room temperature.
  • Compound (2a-2) can be any compound that is an electrophilic reagent such as an alkyl halide.
  • an electrophilic reagent such as an alkyl halide.
  • alkyl halides such as iodomethane, iodoethane, iodopropane, and benzyl bromide
  • alkenyl halides such as allyl bromide and 1-bromo-3-methyl-2-butene
  • alkynyl halides such as propargyl bromide and 1-bromo-2-butyne.
  • One to two equivalents of an electrophilic reagent are preferably used.
  • Solvents for the reaction include, for example, dimethyl sulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, and toluene.
  • the reaction can be achieved in the presence or absence of a base.
  • bases to be used in the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydride, sodium hydride, potassium hydride, butyllithium, methyllithium, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, and potassium bis(trimethylsilyl)amide.
  • one to two equivalents of a base are preferably used.
  • the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • compound (4a) can be prepared from compound (3a) for example, by catalytic reduction under a hydrogen atmosphere in the presence of a metal catalyst, but the reaction conditions are not limited thereto.
  • Specific solvents for the reaction include, for example, methanol, ethanol, propanol, acetic acid, dimethyl sulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, and toluene.
  • metal catalysts include palladium carbon, platinum oxide, and Raney nickel. A metal catalyst is preferably used at 0.5 to 50 weight %. A preferred hydrogen pressure is 1 to 5 atm. The reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • compound (4a-2) are: alkyl halides such as iodomethane, iodoethane, iodopropane, and benzyl bromide; alkenyl halides such as allyl bromide and 1-bromo-3-methyl-2-butene; or alkynyl halides such as propargyl bromide and 1-bromo-2-butyne. These halides are preferably used in an amount of one to two equivalents.
  • Solvents for the reaction include dimethyl sulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, and toluene.
  • the reaction can be carried out in the presence or absence of a base.
  • bases to be used in the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydride, sodium hydride, potassium hydride, butyllithium, methyllithium, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, and potassium bis(trimethylsilyl)amide.
  • 1 to 4 equivalents of a base are preferably used.
  • the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • Compound (5a) can be obtained by reacting compound (4a) with compound (4a-2) in the presence of a copper catalyst and a base. In this case, it is preferable to use 0.1 to 2 equivalents of a copper catalyst and 1 to 10 equivalents of a base.
  • compound (4a-2) may be arylboronic acid, heteroarylboronic acid, or such, in which X is a C 6-10 aryl group which may have one or more substituents or a 5- to 10-membered heteroaryl group which may have one or more substituents, and U 2 is —B(OH) 2 or such.
  • X is a C 6-10 aryl group which may have one or more substituents or a 5- to 10-membered heteroaryl group which may have one or more substituents
  • U 2 is —B(OH) 2 or such.
  • One to three equivalents of compound (4a-2) are preferably used.
  • reaction solvents include dichloromethane, chloroform, 1,4-dioxane, tetrahydrofuran, toluene, pyridine, N,N-dimethylformamide, and N-methylpyrrolidone.
  • Bases include triethylamine, diisopropyl ethyl amine, pyridine, and N,N-dimethylaminopyridine.
  • Copper catalysts include copper (II) acetate, copper (II) trifluoroacetate, copper (II) chloride, and copper (II) iodide. The reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • halogenating agents include, for example, N-chlorosuccinimide, N-bromosuccinimide, and N-iodosuccinimide.
  • a halogenating agent is preferably used in an amount of 1 to 4 equivalents.
  • Solvents for the reaction include acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane.
  • the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • compound (6a) is reacted with compound (7a) to give compound (8a).
  • compound (8a) 1 to 4 equivalents of compound (7a) are preferably used.
  • the reaction can be carried out, for example, in a solvent such as tetrahydrofuran, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, methanol, ethanol, 1,4-dioxane, toluene, and xylene, or in the absence of a solvent.
  • a solvent such as tetrahydrofuran, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, methanol, ethanol, 1,4-dioxane, toluene, and xylene
  • a solvent such as tetrahydrofuran, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, methanol, ethanol, 1,4-dioxane, toluene, and xylene
  • the reaction can be conducted at a temperature ranging from 0° C. to 200° C. in
  • the —NH-protecting group at the 3-position of compound (8a) is removed to give compound (9a).
  • the reaction conditions are selected depending on the type of —NH-protecting group to be removed.
  • the deprotection reaction may be preformed under conditions that are generally used for the protecting group.
  • R p2 is a pivalyloxymethyl group
  • the reaction can be carried out in methanol, or a mixed solution of methanol and tetrahydrofuran, using a base such as sodium methoxide, sodium hydride, or 1,8-diazabicyclo[5,4,0]-7-undecene at a temperature of 0 to 150° C.
  • a base such as sodium methoxide, sodium hydride, or 1,8-diazabicyclo[5,4,0]-7-undecene at a temperature of 0 to 150° C.
  • 0.1 to 2 equivalents of a base are preferably used.
  • R p2 is a trimethylsilylethoxymethyl group
  • the reaction can be carried out in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane, using a fluoride reagent such as tetrabutyl ammonium fluoride or cesium fluoride at a temperature of 0 to 150° C.
  • a fluoride reagent such as tetrabutyl ammonium fluoride or cesium fluoride at a temperature of 0 to 150° C.
  • 1 to 5 equivalents of a fluoride reagent are preferably used.
  • reaction conditions there are no particular limitations on the reaction conditions, and the The reaction can be conducted under standard conditions for chlorination.
  • the reaction can be carried out at a temperature ranging from 0 to 150° C. in a solvent such as phosphorus oxychloride. In this case, it is preferable to use a 10 to 200 times amount of halogenating agent by weight.
  • R p3 is a t-butoxycarbonyl group or such, which is removed under the above-described conditions using phosphorus oxychloride or such, the protecting group should be reintroduced.
  • reaction conditions for the protection there are no particular limitations on the reaction conditions for the protection.
  • the reaction can be carried out using an —NH— protection reagent such as di-t-butyl dicarbonate, in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, or triethylamine at 0 to 150° C.
  • a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, or triethylamine at 0 to 150° C.
  • Compound (11a-2) includes alcohol compounds or phenol compounds represented by A 2 -OH, amine compounds represented by A 2 (R A )NH or such, and thiol compounds represented by A 2 -SH.
  • compound (11a-2) is preferably used in an amount of 1 to 10 equivalents or 5 to 100 times by weight.
  • Solvents for the reaction include acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, and ethanol.
  • the reaction can be carried out in the presence or absence of a base.
  • Bases to be used in the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydride, sodium hydride, potassium hydride, butyllithium, methyllithium, lithium bis(trimethylsilyl) amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, and triethylamine.
  • 1 to 10 equivalents of a base is preferably used.
  • the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • compound (10a) is reacted with compound (13a) in the presence of a metal catalyst to give compound (12a).
  • a metal catalyst In this case, 1 to 50 equivalents of compound (13a) are preferably used.
  • Solvents for the reaction include acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, and ethanol.
  • Metal catalysts include palladium catalyst and copper catalyst.
  • Palladium catalysts include tetrakis triphenylphosphine palladium, palladium acetate, and dibenzylideneacetone palladium.
  • Copper catalyst include copper iodide. It is preferable to use 0.01 to 2 equivalents of a metal catalyst.
  • the reaction can be conducted in the presence of an organophosphorous ligand.
  • organophosphorous ligand examples include o-tolyl phosphine and diphenylphosphinoferrocene. In this case, it is preferable to use 1 to 5 equivalents of an organophosphorous ligand to the metal catalyst.
  • the reaction can be carried out in the presence or absence of a base.
  • Bases to be used in the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydride, sodium hydride, potassium hydride, potassium phosphate, lithium bis trimethylsilyl amide, sodium bis trimethylsilyl amide, potassium bis trimethylsilyl amide, and triethylamine.
  • the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • cyanidation reagents include, for example, sodium cyanide and potassium cyanide. It is preferably used in an amount of 1 to 20 equivalents.
  • Solvents for the reaction include, for example, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, and ethanol.
  • the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • the cyano group of compound (14a) is hydrolyzed to give compound (15a).
  • reaction conditions There are no particular limitations on the reaction conditions, and the reaction can be carried out under conditions generally used for the conversion of a cyano group to a carbamoyl group by hydrolysis.
  • Solvents for the reaction include N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, ethanol, and a mixed solvent of tetrahydrofuran and methanol.
  • the reaction can be carried out in the presence or absence of a base.
  • a base such as potassium hydroxide, sodium hydroxide, lithium hydroxide, or ammonia.
  • the reaction can be achieved after adding an aqueous solution of hydrogen peroxide (preferably an aqueous solution of 30% hydrogen peroxide).
  • the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • R p3 of compound (16a) is removed to give compound (17a).
  • Compounds (11a), (12a), (14a), (15a), and others can be used as compound (16a).
  • the deprotection reaction for R p3 can be carried out under standard reaction conditions for removing an —NH-protecting group.
  • R p3 is a t-butoxycarbonyl group
  • the reaction can be carried out in the presence of an acid such as an anhydrous methanol solution of hydrogen chloride, an anhydrous ethanol solution of hydrogen chloride, an anhydrous dioxane solution of hydrogen chloride, trifluoroacetic acid, or formic acid.
  • an acid such as an anhydrous methanol solution of hydrogen chloride, an anhydrous ethanol solution of hydrogen chloride, an anhydrous dioxane solution of hydrogen chloride, trifluoroacetic acid, or formic acid.
  • compound (18a) is chlorinated to give compound (19a).
  • the reaction conditions there are no particular limitations on the reaction conditions, and the reaction can be conducted under standard conditions for chlorination.
  • the reaction can be carried out in a solvent such as phosphorus oxychloride at a temperature ranging from 0 to 150° C. Preferably 10 to 200 times by weight of chlorination reagent is used.
  • R p3 is a t-butoxycarbonyl group or such, which is removed under the above-described condition using phosphorus oxychloride or such, the protecting group should be reintroduced.
  • reaction conditions for the protection there are no particular limitations on the reaction conditions for the protection, and when R p3 is a t-butoxycarbonyl group, the reaction can be carried out using an —NH— protection reagent such as di-t-butyl dicarbonate, in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane, in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, or triethylamine at a temperature ranging from 0 to 150° C.
  • a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, or triethylamine
  • compound (19a) is partially hydrolyzed to give compound (20a).
  • the reaction is carried out in the presence of a base such as sodium acetate, potassium carbonate, or sodium hydroxide.
  • a base such as sodium acetate, potassium carbonate, or sodium hydroxide.
  • Solvents for the reaction include dimethyl sulfoxide, N-methylpyrrolidone, tetrahydrofuran, water, and mixtures thereof. The reaction can be conducted at a temperature ranging from 0° C. to 100° C.
  • compound (20a) is reacted with compound (21a) to give compound (22a).
  • the reaction can be conducted under the same conditions as used in [Step A2] of production method A.
  • reaction can be conducted under the same conditions as used in [Step A4] of production method A.
  • compound (24a) is reacted with a halogenating agent to give compound (25a).
  • reaction can be conducted under the same conditions as used in [Step A5] of production method A.
  • compound (25a) is chlorinated to give compound (26a).
  • compound (25a) can be reacted with phosphorus oxychloride, phosphorus pentachloride, or a mixture thereof in a solvent or in the absence of a solvent at a temperature of 0 to 150° C.
  • Solvents include, for example, toluene, acetonitrile, and dichloroethane.
  • reaction can be conducted under the same conditions as used in [Step A6] of production method A.
  • compound (1b) is benzylated and the sugar chain is cleaved to give compound (2b).
  • Compound (2b) can be obtained by reacting compound (1b) with benzyl bromide in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, or ethanol, at a temperature of 0 to 150° C., adding 3 to 10 equivalents of hydrochloric acid, and incubating the mixture at a temperature of 0 to 150° C. to cleave the sugar moiety. It is preferable to use 1 to 3 equivalents of benzyl bromide.
  • a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, or ethanol
  • a solvent such as
  • compound (2b) is reacted with a halogenating agent to give compound (3b).
  • the halogenation reaction can be conducted under the same conditions as used in [Step A5] of production method A.
  • compound (5b) is reacted with compound (5b-2) to give compound (6b).
  • the reaction can be conducted under the same condition as used in [Step A2] of production method A.
  • [0478] can be obtained by using compound (8b) represented by H-T 1a , instead of compound (7a) in [Step A6] of production method A described above under the same reaction conditions as used in [Step A6], and then appropriately applying [Step A7] to [Step A13] described above.
  • [0480] can be obtained by using compound (8b) represented by H-T 1a , instead of compound (3b) in [Step B3] of production method B described above under the same reaction conditions as used in [Step B3] and then appropriately applying [Step B4] to [Step B6] described above.
  • compound (8b) include piperidin-3-yl carbamic acid t-butyl ester.
  • Compound (3c) can be obtained, for example, by heating an ethanol solution of compound (2c) under reflux in the presence of an acid such as sulfuric acid or hydrochloric acid.
  • an acid such as sulfuric acid or hydrochloric acid.
  • the reaction conditions are not limited thereto. In this reaction, it is preferable to use one to two equivalents of an acid.
  • compound (7c) is thioamidated to give compound (8c).
  • Solvents for the reaction include methanol, ethanol, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane.
  • Thioamidation reagents include ammonium sulfide, sodium sulfide, and hydrogen sulfide. It is preferable to use 2 to 10 equivalents of a thioamidation reagent.
  • the reaction is carried out in the presence of a base such as triethylamine or N,N-diisopropylethylamine.
  • a base such as triethylamine or N,N-diisopropylethylamine.
  • the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • compound (8c) is reacted with a methylating reagent to give compound (9c).
  • Methylating reagents include trimethyl oxonium tetrafluoroborate, methyl sulfate, methyl iodide, and trimethyl phosphite. It is preferable to use 1.0 to 1.5 equivalent of the methylating reagent.
  • compound (9c) can be obtained by carrying out the reaction in a halogenated solvent such as dichloromethane at a temperature ranging from 0° C. to 50° C.
  • a halogenated solvent such as dichloromethane
  • compound (9c) can be obtained by carrying out the reaction in the presence of a base such as potassium carbonate, triethylamine, or N,N-diisopropylethylamine. In this case, it is preferable to use 1.0 to 1.5 equivalent of a base.
  • Solvents for the reaction include acetone, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane. The reaction can be performed at a temperature ranging from 0° C. to 100° C.
  • reaction conditions for the hydrolysis There are no particular limitations on the reaction conditions for the hydrolysis.
  • the reaction can be carried out in a mixed solvent of ethanol and water in the presence of an acid such as sulfuric acid, hydrochloric acid, or p-toluenesulfonic acid, at a temperature ranging from 0° C. to 80° C. In this case, it is preferable to use 5 to 50 equivalents of the acid.
  • R p3 is a group, such as a t-butoxycarbonyl group, which is removed under the above-described condition, the protecting group should be reintroduced. There are no particular limitations on the reaction conditions for the introduction of this protecting group.
  • R p3 is a t-butoxycarbonyl group
  • the reaction can be carried out using a reagent such as t-butyl dicarbonate in a solvent such as dichloromethane, chloroform, N,N-dimethylformamide, or tetrahydrofuran, in the presence of a base such as pyridine, 4-aminopyridine, triethylamine, and N,N-diisopropylethylamine, at a temperature ranging from 0 to 80° C. In this case, it is preferable to use 2 to 3 equivalents of a base.
  • reaction conditions for the reduction There are no particular limitations on the reaction conditions for the reduction.
  • the reaction can be achieved by reacting compound (10c) with hydrogen in the presence of Raney nickel in a solvent such as benzene, ethanol, 2-propanol, or acetone, at a temperature ranging from 0° C. to 50° C., or alternatively reacting compound (10c) with a reducing agent such as sodium borohydride, in a solvent such as methanol, ethanol, or 2-methyl-2-propanol, or in a mixed solvent of water and tetrahydrofuran at a temperature ranging from 0° C.
  • a reducing agent such as sodium borohydride
  • compound (10c) with a reducing agent such as sodium borohydride, in the presence of 1 to 5 equivalents of a mercury salt such as mercuric acetate in a solvent such as methanol, ethanol, or 2-methyl-2-propanol at a temperature ranging from 0° C. to 50° C. It is preferable to use two to three equivalents of a reducing agent.
  • a reducing agent such as sodium borohydride
  • compound (12c) can be obtained by carrying out the reaction in a solvent such as dichloromethane or chloroform, at a temperature ranging from 20° C. to 80° C.
  • compound (12c) can also be obtained by carrying out the reaction under standard conditions for the oxidation of a primary alcohol to aldehyde, such as Swern oxidation. It is preferable to use 5 to 20 equivalents of an oxidant.
  • compound (12c) is reacted with compound (13c) to give compound (17c).
  • compound (13c) it is preferable to use 2 to 10 equivalents of compound (13c).
  • Compound (17c) can be obtained, for example, by combining compounds (12c) and (13c) in a solvent such as methanol, ethanol, 1-methyl-2-pyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane, or in the absence of solvent, and reacting the mixture at a temperature of 20 to 150° C.
  • a solvent such as methanol, ethanol, 1-methyl-2-pyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane
  • the reaction conditions are not limited thereto.
  • compound (12c) is reacted with hydrazine to give compound (15c).
  • the reaction can be conducted under the same conditions as used in [Step C11] of production method C. It is preferable to use 2 to 10 equivalents of hydrazine.
  • reaction conditions for the hydrolysis there are no particular limitations on the reaction conditions for the hydrolysis.
  • compound (19c) can be obtained by incubating compound (18c) in the presence of a base at a temperature ranging from 0° C. to 100° C.
  • Solvents for the reaction include methanol, ethanol, tetrahydrofuran, water, or mixtures thereof.
  • Bases include lithium hydroxide, sodium hydroxide, and potassium hydroxide. It is preferable to use 1 to 2 equivalents of a base.
  • compound (19c) is reacted with a reducing agent to give compound (20c).
  • the reduction can be achieved under a standard condition for the reduction of carboxylic acid to methyl alcohol.
  • Reducing agents include borane derivatives such as borane-tetrahydrofuran complex and borane-methyl sulfide complex, and sodium borohydride. It is preferable to use 5 to 30 equivalents of a reducing agent.
  • compound (20c) can be obtained by carrying out the reaction using a solvent such as 1,4-dioxane, tetrahydrofuran, or dimethoxyethane at a temperature ranging from ⁇ 78° C. to 35° C.
  • a solvent such as 1,4-dioxane, tetrahydrofuran, or dimethoxyethane at a temperature ranging from ⁇ 78° C. to 35° C.
  • compound (21c) is reacted with a silylating agent in the presence of a base to give compound (22c).
  • Solvents for the reaction include dichloromethane, N,N-dimethylformamide, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane.
  • Bases include imidazole, pyridine, 4-dimethylaminopyridine, triethylamine, and N,N-diisopropylethylamine.
  • Silylating agents include t-butyldimethylchlorosilane, and t-butylchlorodiphenylsilane. It is preferable to use 1.0 to 1.5 equivalent of a base and 1.0 to 1.5 equivalent of a silylating agent.
  • the reaction can be conducted at a temperature ranging from 0° C. to 80° C.
  • reaction can be conducted under the same condition as used in [Step C7] of production method C.
  • Compound (24c) can be obtained by carrying out the reaction in a mixed solvent of ethanol and water in the presence of an acid such as sulfuric acid, hydrochloric acid, or p-toluenesulfonic acid, at a temperature ranging from 50° C. to 100° C.
  • an acid such as sulfuric acid, hydrochloric acid, or p-toluenesulfonic acid
  • —NH— is re-protected through a protection reaction.
  • a reagent such as t-butyl dicarbonate
  • a solvent such as dichloromethane, chloroform, N,N-dimethylformamide, or tetrahydrofuran
  • a base such as pyridine, 4-aminopyridine, triethylamine, or N,N-diisopropyl ethylamine, at a temperature ranging from 0 to 80° C.
  • the reaction is not limited thereto.
  • compound (1d-2) includes, for example, alkyl halides such as iodomethane, iodoethane, iodopropane, benzyl bromide, 2-bromoacetophenone, chloromethyl benzyl ether, and bromoacetonitrile; alkenyl halides such as allyl bromide and 1-bromo-3-methyl-2-butene; and alkynyl halides such as propargyl bromide and 1-bromo-2-butyne. It is preferable to use 1 to 1.5 equivalent of compound (1d-2).
  • alkyl halides such as iodomethane, iodoethane, iodopropane, benzyl bromide, 2-bromoacetophenone, chloromethyl benzyl ether, and bromoacetonitrile
  • alkenyl halides such as allyl bromide and 1-bromo-3-methyl-2
  • Solvents for the reaction include N,N-dimethylformamide, N-methylpyrrolidone, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, and dichloromethane.
  • the reaction can be carried out in the presence or absence of a base.
  • Bases to be used in the reaction include 1,8-diazabicyclo[5,4,0]undecene, triethylamine, N,N-diisopropylethylamine, and sodium hydride. In this case, it is preferable to use 1 to 1.5 equivalent of the base.
  • the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • Solvents for the reaction include a mixed solvent of water and a solvent from N,N-dimethylformamide, N-methylpyrrolidone, tetrahydrofuran, 1,2-dimethoxyethane, and 1,4-dioxane.
  • Nitrite salts include sodium nitrite and potassium nitrite. It is preferable to use 3 to 5 equivalents of a nitrite.
  • the reaction can be conducted at a temperature ranging from 20° C. to 120° C.
  • compound (3d) is reacted with ammonia to give compound (4d). It is preferable to use 10 to 20 equivalents of ammonia.
  • the reaction can be carried out in a solvent such as methanol, ethanol, or 1,4-dioxane at a temperature ranging from 20° C. to 200° C.
  • a solvent such as methanol, ethanol, or 1,4-dioxane
  • compound (4d) is subjected to catalytic reduction under hydrogen atmosphere or in the presence of 2 to 3 equivalents of hydrazine using a metal catalyst to give compound (5d).
  • Solvents for the reaction include methanol, ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, water, or a mixed solvent thereof.
  • Metal catalysts include palladium carbon, platinum oxide, and Raney nickel. It is preferable to use a metal catalyst in the amount of 0.5 to 10% by weight. The reaction can be conducted at a temperature ranging from 0° C. to 150° C.
  • the reaction is carried out in the presence of a carboxylic anhydride such as acetic anhydride.
  • a carboxylic anhydride such as acetic anhydride.
  • Orthoformate esters include methyl orthoformate, and ethyl orthoformate. It is preferable to use 1 to 20 times as much orthoformate ester by weight and 3 to 10 equivalents of carboxylic anhydride.
  • the reaction can be conducted at a temperature ranging from 20° C. to 200° C.
  • Protecting reagents include N,N-dimethylsulfamoyl chloride, trityl chloride, di-t-butyl dicarbonate, and benzyl bromide. It is preferable to use 1 to 1.5 equivalent of a protecting reagent.
  • Solvents for the reaction include dichloromethane, chloroform, carbon tetrachloride, toluene, N,N-dimethylformamide, and tetrahydrofuran.
  • Bases include pyridine, 4-dimethylaminopyridine, 1,8-diazabicyclo[5,4,0]undecene, triethylamine, and N,N-diisopropylethylamine.
  • the protecting reagent is di-t-butyl dicarbonate
  • 0.005 to 0.1 equivalent of 4-dimethylaminopyridine is used preferably.
  • the reaction can be conducted at a temperature ranging from 20° C. to 200° C.
  • reaction conditions there are no particular limitations on the reaction conditions.
  • the reaction is carried out as follows.
  • Compound (7d) is reacted with a base at a temperature ranging from ⁇ 100° C. to 20° C., and then a chlorinating reagent is reacted thereto.
  • This reaction produces compound (8d).
  • Compound (8d) can also be obtained by reacting compound (7d) with a base in the presence of a chlorination reagent.
  • Solvents for the reaction include, for example, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, and 1,4-dioxane.
  • Bases include n-butyllithium, t-butyllithium, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, and magnesium diisopropylamide. It is preferable to use 1 to 1.5 equivalent of a base.
  • Chlorinating reagents include hexachloroethane, and N-chloro succinimide. It is preferable to use 1 to 3 equivalents of a chlorination reagent.
  • R 1 is a benzyloxymethyl group
  • compound (11d) is reacted with 3 to 10 equivalents of boron tribromide, boron trichloride, or such in a solution such as dichloromethane at a temperature ranging from ⁇ 100° C. to 20° C. This reaction produces compound (13d).
  • —NH— is re-protected through a protection reaction.
  • a reagent such as di-t-butyl dicarbonate
  • a solvent such as dichloromethane, chloroform, N,N-dimethylformamide, or tetrahydrofuran
  • a base such as pyridine, 4-aminopyridine, triethylamine, or N,N-diisopropylethylamine, at a temperature ranging from 0 to 80° C.
  • the reaction is not limited thereto.
  • compound (13d) is reacted with compound (13d-2) to give compound (14d).
  • the reaction can be conducted under the same conditions as used in [Step D1] of production method D.
  • the deprotection can be achieved under standard reaction conditions depending on the type of protecting group.
  • the deprotection can be achieved by carrying out the reaction using a base such as sodium hydroxide, potassium carbonate, and ammonia, in tetrahydrofuran, N,N-dimethylformamide, methanol, ethanol, water, or a mixed solvent thereof at a temperature ranging from 0° C. to 100° C.
  • a base such as sodium hydroxide, potassium carbonate, and ammonia
  • An alcohol (X—OH) can be introduced using Mitsunobu's reaction.
  • compound (16d) can be obtained by reacting an alcohol (X—OH) with an azodicarboxylic acid dialkyl ester and triphenylphosphine in a solvent such as tetrahydrofuran, at a temperature ranging from ⁇ 70° C. to 50° C.
  • reaction can be conducted under the same conditions as used in [Step A6] of production method A.
  • [0589] can be obtained by using compound (8b) represented by H-T 1a , instead of compound (6c), in [Step C5] or [Step C15] of production method C described above under the same reaction conditions as used in [Step C5], and then appropriately applying [Step C6] to [Step C21] described above.
  • [0591] can be obtained by using compound (8b) represented by H-T 1a , instead of compound (9d) in [Step D8] of production method D described above under the same reaction conditions as used in [Step D8], and then appropriately applying [Step D9] to [Step D13] described above.
  • Solvents for the reaction include methanol, ethanol, tetrahydrofuran, water, or mixtures thereof.
  • Reducing agents includes, iron, tin, and zinc.
  • Catalysts include hydrochloric acid and ammonium salts such as ammonium chloride. The reaction can be conducted at a temperature ranging from 20° C. to 120° C.
  • reaction conditions there are no particular limitations on the reaction conditions.
  • Compound (2h) can be obtained by reacting compound (1h) with hydrogen peroxide in the presence of a base at a temperature ranging from ⁇ 20° C. to 50° C.
  • Solvents include methanol, ethanol, tetrahydrofuran, water, or a solvent mixture thereof.
  • Bases include ammonia and alkyl amines such as triethylamine.
  • compound (1i) is reacted with an alkyl metal agent or an aryl metal agent to give compound (2i).
  • reaction conditions there are no particular limitations on the reaction conditions.
  • the reaction is carried out as follows.
  • Compound (1i) may be reacted with an agent such as alkyllithium, aryllithium, alkyl Grignard reagent, or aryl Grignard reagent, in a solvent such as diethyl ether or tetrahydrofuran, at a temperature ranging from ⁇ 100° C. to 100° C.
  • the compound may be reacted with alkylzinc or arylzinc in a solvent such as N,N-dimethylformamide or 1-methyl-2-pyrrolidone, at a temperature ranging from 0° C. to 50° C.
  • compound (2i) is oxidized to give compound (3i)
  • a typical reagent that is generally used in the oxidation of an alcohol can be used as the oxidant.
  • manganese dioxide can be used as the oxidant in a solvent such as dichloromethane or chloroform, at a temperature within the range of 20 to 100° C.
  • sulfur trioxide pyridine can be used as the oxidant in a solvent such as dimethyl sulfoxide, at a temperature within the range of 20 to 100° C.
  • Dess-Martin periodinane may be used in a solvent such as dichloromethane or chloroform, at a temperature within the range of ⁇ 50 to 50° C.
  • Cyanidation agents include sodium cyanide, and potassium cyanide.
  • Catalysts include acetic acid.
  • Solvents include, for example, acetonitrile. The reaction can be conducted at a temperature ranging from 0° C. to 100° C.
  • Dehydrating agents include, for example, phosphorus oxychloride.
  • Bases include alkyl amines such as triethylamine.
  • Solvents include dichloromethane, and chloroform.
  • the reaction can be carried out in the absence of solvent. The reaction can be conducted at a temperature ranging from 0° C. to 100° C.
  • Compound (5k) can be obtained, for example, by reacting a mixture of compounds (3k) and (4k) in a solvent such as methanol, ethanol, 1-methyl-2-pyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane, or in the absence of solvent at a temperature ranging from 20° C. to 200° C.
  • a solvent such as methanol, ethanol, 1-methyl-2-pyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane
  • the reaction conditions are not limited thereto.
  • the deprotection reaction for R p5 can be carried out under standard reaction conditions for removing an —NH-protecting group.
  • R p5 is a benzyl group
  • the reaction can be achieved using a metal such as lithium or sodium in liquid ammonia at a temperature within the range of ⁇ 78° C. to ⁇ 30° C.
  • Oxidants include salts such as iron (III) chloride.
  • Solvents include methanol, ethanol, and water. The reaction can be conducted at a temperature ranging from 20° C. to 100° C.
  • —NH— is re-protected through a protection reaction.
  • a reagent such as di-t-butyl dicarbonate
  • a solvent such as dichloromethane, chloroform, N,N-dimethylformamide, or tetrahydrofuran
  • a base such as pyridine, 4-aminopyridine, triethylamine, or N,N-diisopropylethylamine, at a temperature ranging from 0 to 80° C.
  • the reaction is not limited thereto.
  • the reaction can be conducted at a temperature ranging from 20° C. to 150° C.
  • Solvents for the reaction include methanol, ethanol, water, and a mixed solvent thereof.
  • Reducing agents include tin salts such as tin chloride.
  • Solvents include concentrated hydrochloric acid. The reaction can be conducted at a temperature ranging from 20° C. to 150° C.
  • the reaction can be achieved using a solvent such as acetonitrile or tetrahydrofuran.
  • the reaction can be conducted at a temperature ranging from 20° C. to 100° C.
  • Compound (7n) can be obtained, for example, by reacting compound (6n) with osmic acid and sodium periodate in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, or water at a temperature ranging from 20° C. to 100° C.
  • a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, or water at a temperature ranging from 20° C. to 100° C.
  • the reaction conditions are not limited to this example.
  • reaction conditions There are no particular limitations on the reaction conditions.
  • the reaction can be conducted under standard reaction conditions to be used for chlorination.
  • Compound (8n) can be obtained, for example, by using a reagent such as phosphorus pentachloride in a solvent such as phosphorus oxychloride, at a temperature of 0 to 150° C.
  • Bases include sodium hydride and lithium diisopropylamide.
  • Solvents include, for example, tetrahydrofuran and N,N-diformamide. The reaction can be conducted at a temperature ranging from 0° C. to 100° C.
  • Solvents for the reaction include toluene, t-butanol, tetrahydrofuran, and dichloromethane.
  • Bases include tertiary amines such as triethylamine and diisopropylethylamine. The reaction can be conducted at a temperature ranging from ⁇ 50° C. to 50° C.
  • reaction can be achieved in t-butanol at a temperature ranging from 50° C. to 100° C.
  • Acids include hydrochloric acid, sulfuric acid, and trifluoroacetic acid.
  • Solvents include methanol, ethanol, 1,4-dioxane, water, and mixtures thereof. The reaction can be conducted at a temperature ranging from 0° C. to 50° C.
  • a typical NH group-protecting reagent that is generally used in protecting NH groups can be used as an NH group-protecting reagent.
  • R p3 is a t-butoxycarbonyl group
  • the reaction can be achieved at a temperature ranging from 0 to 80° C. using a reagent such as di-t-butyl dicarbonate, in a solvent such as dichloromethane, chloroform, N,N-dimethylformamide, and tetrahydrofuran, in the presence of a base such as pyridine, 4-aminopyridine, triethylamine, and N,N-diisopropylethylamine.
  • reaction solvents include tetrahydrofuran, methanol, and ethanol.
  • Acids include inorganic acids such as hydrochloric acid and sulfuric acid. The reaction can be conducted at a temperature ranging from 0° C. to 100° C.
  • Bases include sodium hydride, potassium t-butoxide, and 8-diazabicyclo[5.4.0]-7-undecene.
  • Solvents include dichloromethane, tetrahydrofuran, and N,N-dimethylformamide. The reaction can be conducted at a temperature ranging from 0° C. to 100° C.
  • Methanol can be used as solvent.
  • the reaction can be conducted at a temperature ranging from 0° C. to 80° C.
  • Reaction solvents include methanol, ethanol, and water.
  • the reaction can be conducted at a temperature ranging from 20° C. to 150° C.
  • R 1 is defined as in [1] above;
  • R p5 represents a t-butoxycarbonyloxy group, a trityl group, or a group represented by the formula —SO 2 NH 2 ;
  • T 10 represents a halogen atom or a hydrogen atom]
  • R 1 is defined as in [1] above;
  • T 11 represents a halogen atom or a group represented by the formula:
  • T 13 represents a t-butoxycarbonyl group, a benzyloxycarbonyl group, or a formyl group];
  • R 1 and X are defined as in [1] above;
  • T 12 represents a halogen atom
  • X is defined as in [1] above, but excluding the case where X is a benzyl group;
  • T 21 and T 22 each independently represent a halogen atom
  • T 11 represents a halogen atom or a group represented by the formula:
  • T 13 represents a t-butoxycarbonyl group, a benzyloxycarbonyl group, or a formyl group];
  • X and R 1 are defined as in [1] above;
  • T 22 represents a halogen atom
  • T 13 represents a t-butoxycarbonyl group, a benzyloxycarbonyl group, or a formyl group].
  • the methods indicated above are representative methods for producing compound (I) of the present invention.
  • the starting compounds and various reagents to be used in the methods for producing compounds of the present invention may be salts or hydrates, or solvates depending on the type of starting materials, solvents to be used, or such, and are not limited as long as they do not inhibit the reactions.
  • the type of solvents to be used depends on the types of starting compounds, reagents to be used, or such, and is not limited as long as it does not inhibit the reactions and dissolves starting materials to some extent.
  • various isomers of compound (I) of the present invention can be purified and isolated by typical isolation means, for example, including recrystallization, diastereomer salt method, enzyme-based separation, and various chromatographic methods (for example, thin layer chromatography, column chromatography, and gas chromatography).
  • Compounds of the present invention, salts thereof, or hydrates thereof can be formulated into tablets, powders, particles, granules, coated tablets, capsules, syrups, troches, inhalants, suppositories, injections, ointments, eye ointments, eye drops, nasal drops, ear drops, epithem, lotions, etc. by conventional methods.
  • Such formulation can be achieved by using typical diluting agents, binders, lubricants, colorants, flavoring agents, and if required, stabilizers, emulsifiers, absorbefacients, surfactants, pH modulators, preservatives, antioxidants, etc., and materials commonly used as ingredients of pharmaceutical preparations according to conventional methods.
  • an oral preparation can be produced by combining a compound of the present invention or a pharmaceutically acceptable salt thereof with a diluting agent, and if required, a binder, a disintegrating agent, a lubricant, a colorant, a flavoring agent, or such, and formulating the mixture into powders, particles, granules, tablets, coated tablets, capsules, or the like according to conventional methods.
  • the materials include, for example, animal and vegetable oils such as soya bean oil, beef tallow, and synthetic glyceride; hydrocarbons such as liquid paraffin, squalane, and solid paraffin; ester oils such as octyldodecyl myristate and isopropyl myristate; higher alcohols such as cetostearyl alcohol and behenyl alcohol; silicon resins; silicone oils; surfactants such as polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerol fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, and polyoxyethylene polyoxypropylene block co-polymer; water-soluble polymers such as hydroxyethyl cellulose, poly-acrylic acid, carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone, and methyl cellulose; lower alcohols such as ethanol and isopropanol; polyhydric alcohols such as
  • Diluting agents include, for example, lactose, corn starch, white sugar, glucose, mannitol, sorbitol, crystal cellulose, and silicon dioxide.
  • Binders include, for example, polyvinyl alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, polypropylene glycol-polyoxyethylene block co-polymer, and meglumine.
  • Disintegrating agents include, for example, starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin, pectin, and calcium carboxymethyl cellulose.
  • Lubricants include, for example, magnesium stearate, talc, polyethylene glycol, silica, and hydrogenated vegetable oil.
  • Colorants include those pharmaceutically acceptable.
  • Flavoring agents include cocoa powder, peppermint camphor, aromatic powder peppermint oil, Borneo camphor, and cinnamon powder. Tablets and granules may be coated with sugar, or if required, other appropriate coatings can be made.
  • Solution such as syrups or injectable preparations, to be administered can be formulated by combining a compound of the present invention or a pharmaceutically acceptable salt thereof with a pH modulator, a solubilizing agent, an isotonizing agent, or such, and if required, with an auxiliary solubilizing agent, a stabilizer, or the like, according to conventional methods.
  • Methods for producing an external preparation are not limited and such preparations can be produced by conventional methods. Specifically, various materials typically used for producing pharmaceuticals, quasi drugs, cosmetics, and such can be used as base materials for the external formulation.
  • base materials to be used include, for example, animal and vegetable oils, mineral oils, ester oil, wax, higher alcohols, fatty acids, silicone oil, surfactants, phospholipids, alcohols, polyhydric alcohols, water-soluble polymers, clay minerals, and pure water.
  • external preparations of the present invention can contain, as required, pH modulators, antioxidants, chelating agents, antibacterial/antifungal agents, coloring matters, odoriferous substances, etc. But this does not limit the type of base materials that are to be used in an external preparation of the present invention.
  • the preparation may contain differentiation inducers, blood flow improving agents, antimicrobial agents, antiphlogistics, cell activators, vitamins, amino acids, humectants, keratolytic agents, etc.
  • the amount of base materials listed above is adjusted within a concentration range used for producing typical external preparations.
  • a compound of the present invention or a salt thereof, or a hydrate thereof is administered
  • the forms of a compound are not limited and a compound can be given orally or parenterally by a conventional method.
  • a compound can be administered as a dosage form such as tablets, powders, granules, capsules, syrups, troches, inhalants, suppositories, injections, ointments, eye ointments, eye drops, nasal drops, ear drops, epithems, and lotions.
  • the dose of a pharmaceutical of the present invention can be selected appropriately based on symptom severity, age, sex, weight, forms of compounds, type of salts, specific type of diseases, etc.
  • the dose varies depending on the patient's disease, symptom severity, age and sex, drug susceptibility, etc.
  • a pharmaceutical agent of this invention is administered once or several times at a dose of approx. 0.03 to approx. 1000 mg/adult/day, preferably 0.1 to 500 mg/adult/day, more preferably 0.1 to 100 mg/adult/day.
  • An injection can be given at a dose of approx. 1 to approx. 3000 ⁇ g/kg, preferably approx. 3 to approx. 1000 ⁇ g/kg.
  • reaction solution was concentrated to 50 ml, and washed with 20 ml of t-butyl methyl ether.
  • the solution was acidified with concentrated hydrochloric acid.
  • the resulting precipitate was collected by filtration, and washed successively with 10 ml of water and 10 ml of t-butyl methyl ether. Thus, 1.03 g of the title compound was obtained.
  • reaction mixture was extracted with ethyl acetate-water, and the organic layer was washed with 1N hydrochloric acid, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was triturated with diethyl ether. The crystals were collected by filtration, and washed with diethyl ether. Thus, 3.0 g of the title compound was obtained as a white solid.
  • the resulting mixture was stirred at room temperature for three hours.
  • the reaction mixture was diluted with ethyl acetate and washed with water.
  • the organic layer was dried over anhydrous magnesium sulfate, then filtered.
  • the filtrate was concentrated, and the residue was purified by silica gel column chromatography.
  • This solution was poured into a suspension consisting of 7 g of di-t-butyl dicarbonate, 50 ml of tetrahydrofuran, 100 g of sodium bicarbonate, and 200 ml of water, and the mixture was stirred at room temperature for one hour.
  • the reaction mixture was diluted with ethyl acetate, and the mixture was washed with water.
  • the organic layer was dried over anhydrous magnesium sulfate, then filtered. The filtrate was concentrated, and the residue was purified by silica gel column chromatography.
  • Example (11b) Using ethanol instead of methanol in Example (11b), the trifluoroacetate of the title compound was obtained by the same method as used in Example 11. This compound was purified by chromatography using NH-silica gel. Thus, the title compound was obtained from the fraction eluted with ethyl acetate-methanol (20:1).
  • Example 13 Using ethyl 1-hydroxycyclopropanecarboxylate instead of ethyl 2-hydroxyacetate in Example 13, the trifluoroacetate of the title compound was obtained by the same method as used in Example 13. The compound was purified by chromatography using NH-silica gel. Thus, the title compound was obtained from the fraction eluted with ethyl acetate-methanol (20:1).
  • reaction solution was concentrated, and the residue was dissolved in trifluoroacetic acid.
  • the mixture was concentrated, and the residue was purified by reverse-phase high performance liquid chromatography (using an acetonitrile-water mobile phase (containing 0.1% trifluoroacetic acid)) to give 3.38 mg of the title compound.
US10/457,002 2002-06-06 2003-06-06 Condensed imidazole derivatives Abandoned US20040116328A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/212,407 US20060063787A1 (en) 2002-06-06 2005-08-26 Condensed imidazole derivatives
US12/199,982 US7772226B2 (en) 2002-06-06 2008-08-28 Condensed imidazole derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2002166069 2002-06-06
JP2002-166069 2002-06-06
JP2002-209373 2002-07-18
JP2002209373 2002-07-18
JP2002-307750 2002-10-23
JP2002307750 2002-10-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/212,407 Continuation US20060063787A1 (en) 2002-06-06 2005-08-26 Condensed imidazole derivatives

Publications (1)

Publication Number Publication Date
US20040116328A1 true US20040116328A1 (en) 2004-06-17

Family

ID=29740540

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/516,971 Abandoned US20060100199A1 (en) 2002-06-06 2003-06-03 Novel condensed imidazole derivatives
US10/457,002 Abandoned US20040116328A1 (en) 2002-06-06 2003-06-06 Condensed imidazole derivatives
US11/212,407 Abandoned US20060063787A1 (en) 2002-06-06 2005-08-26 Condensed imidazole derivatives
US12/199,982 Expired - Fee Related US7772226B2 (en) 2002-06-06 2008-08-28 Condensed imidazole derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/516,971 Abandoned US20060100199A1 (en) 2002-06-06 2003-06-03 Novel condensed imidazole derivatives

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/212,407 Abandoned US20060063787A1 (en) 2002-06-06 2005-08-26 Condensed imidazole derivatives
US12/199,982 Expired - Fee Related US7772226B2 (en) 2002-06-06 2008-08-28 Condensed imidazole derivatives

Country Status (19)

Country Link
US (4) US20060100199A1 (US20040116328A1-20040617-C00011.png)
EP (1) EP1514552A4 (US20040116328A1-20040617-C00011.png)
JP (2) JP3675813B2 (US20040116328A1-20040617-C00011.png)
KR (1) KR100985160B1 (US20040116328A1-20040617-C00011.png)
CN (2) CN100469778C (US20040116328A1-20040617-C00011.png)
AU (1) AU2003241960B2 (US20040116328A1-20040617-C00011.png)
BR (1) BR0311697A (US20040116328A1-20040617-C00011.png)
CA (1) CA2485641C (US20040116328A1-20040617-C00011.png)
HK (2) HK1078869A1 (US20040116328A1-20040617-C00011.png)
IL (1) IL165178A0 (US20040116328A1-20040617-C00011.png)
IS (1) IS7625A (US20040116328A1-20040617-C00011.png)
MX (1) MXPA04012226A (US20040116328A1-20040617-C00011.png)
NO (1) NO20050054L (US20040116328A1-20040617-C00011.png)
NZ (1) NZ536794A (US20040116328A1-20040617-C00011.png)
PL (1) PL374007A1 (US20040116328A1-20040617-C00011.png)
RU (1) RU2297418C9 (US20040116328A1-20040617-C00011.png)
TW (1) TWI273104B (US20040116328A1-20040617-C00011.png)
WO (1) WO2003104229A1 (US20040116328A1-20040617-C00011.png)
ZA (1) ZA200500041B (US20040116328A1-20040617-C00011.png)

Cited By (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034014A1 (en) * 2000-07-04 2004-02-19 Kanstrup Anders Bendtz Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US20040082570A1 (en) * 2002-02-25 2004-04-29 Eisai Co., Ltd. Xanthine derivative and DPPIV inhibitor
US20040097510A1 (en) * 2002-08-21 2004-05-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20040122228A1 (en) * 2002-08-22 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138215A1 (en) * 2002-11-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138214A1 (en) * 2002-11-08 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040166125A1 (en) * 2002-08-22 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US20040242566A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004108730A1 (en) * 2003-06-05 2004-12-16 Fujisawa Pharmaceutical Co., Ltd. 1h-imidazo`4,5-d!pyridazines as dpp-iv inhibitors for the treatment of niddm
WO2004111051A1 (de) * 2003-06-18 2004-12-23 Boehringer Ingelheim International Gmbh Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel
US20050020574A1 (en) * 2002-12-03 2005-01-27 Boehringer Ingelheim Pharma Gmbh Co. Kg New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
US20050070535A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2005058901A1 (de) * 2003-12-17 2005-06-30 Boehringer Ingelheim International Gmbh Neue 2-(piperazin-1-yl)- und 2-([1,4]diazepan-1-yl)- imidazo[4,5-d]pyridazin-4-one, deren herstellung und deren verwendung als arzneimittel zur bekämpfung von diabetes mellitus
US20050143377A1 (en) * 2003-12-23 2005-06-30 Boehringer Ingelheim International Gmbh Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions
WO2005061505A1 (en) * 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic imidazolyl pyrimidin-4-one cannabinoid receptor ligands and uses thereof
US20050171093A1 (en) * 2003-12-17 2005-08-04 Boehringer Ingelheim International Gmbh New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions
US20050187227A1 (en) * 2004-02-23 2005-08-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US20050203095A1 (en) * 2004-03-13 2005-09-15 Boehringer Ingelheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US20050234108A1 (en) * 2004-02-18 2005-10-20 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20050261352A1 (en) * 2004-05-10 2005-11-24 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US20060004074A1 (en) * 2004-06-24 2006-01-05 Boehringer Ingelheim International Gmbh New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US20060058323A1 (en) * 2004-09-11 2006-03-16 Boehringer Ingelheim International Gmbh New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060063787A1 (en) * 2002-06-06 2006-03-23 Eisai Co., Ltd. Condensed imidazole derivatives
US20060079541A1 (en) * 2004-09-14 2006-04-13 Boehringer Ingelheim International Gmbh 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060094722A1 (en) * 2002-09-26 2006-05-04 Eisai Co., Ltd. Combination drug
US20060111362A1 (en) * 2002-12-04 2006-05-25 Eisai Co., Ltd. 1,3-Dihydroimidazole ring compound
US20060142310A1 (en) * 2004-11-05 2006-06-29 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US20060154866A1 (en) * 2005-01-10 2006-07-13 Zhi-Liang Chu Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US20060247226A1 (en) * 2001-02-24 2006-11-02 Frank Himmelsbach Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070027168A1 (en) * 2005-07-30 2007-02-01 Waldemar Pfrengle 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US7179809B2 (en) 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US20070098781A1 (en) * 2005-08-11 2007-05-03 Loeffler Bernd M Modified release compositions for DPP-IV inhibitors
US20070219178A1 (en) * 2003-12-04 2007-09-20 Eisai Co., Ltd. Preventive or therapeutic agents for multiple sclerosis
US20070259900A1 (en) * 2006-05-04 2007-11-08 Peter Sieger Polymorphs
US20070281940A1 (en) * 2006-05-04 2007-12-06 Klaus Dugi Uses of dpp-iv inhibitors
US20080107731A1 (en) * 2006-05-04 2008-05-08 Anja Kohlrausch Dpp iv inhibitor formulations
US20080318922A1 (en) * 2004-12-24 2008-12-25 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic Pyrrole Derivatives
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US7550455B2 (en) 2003-11-27 2009-06-23 Boehringer Ingelheim International Gmbh 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
WO2009111501A1 (en) * 2008-03-04 2009-09-11 Smithkline Beecham Corporation Derivatives of imidazo [4, 5-d] pyridazine and their use as anti-viral compounds
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20100190750A1 (en) * 2006-04-11 2010-07-29 Arena Pharmaceuticals, Inc. GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto
US20100203038A1 (en) * 2006-04-11 2010-08-12 Arena Pharmaceuticals, Inc. Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual
US20100203556A1 (en) * 2008-04-07 2010-08-12 Arena Pharmaceuticals, Inc. Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy
US7781584B2 (en) 2004-03-15 2010-08-24 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7825242B2 (en) 2004-07-16 2010-11-02 Takeda Pharmaceutical Company Limted Dipeptidyl peptidase inhibitors
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
US20110009433A1 (en) * 2008-03-10 2011-01-13 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrrole compound
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20110092510A1 (en) * 2008-06-03 2011-04-21 Boehringer Ingelheim International Gmbh Dpp-iv inhibitors for use in the treatment of nafld
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US20110206766A1 (en) * 2008-04-03 2011-08-25 Boehringer Ingelheim International Gmbh Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8071583B2 (en) 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012089127A1 (en) * 2010-12-29 2012-07-05 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014100065A1 (en) * 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
WO2016042775A1 (en) * 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
EP2994128A4 (en) * 2013-05-10 2016-11-23 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9988399B2 (en) 2013-05-10 2018-06-05 Gilead Apollo, Llc Bicyclic compounds as ACC inhibitors and uses thereof
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US10208063B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
US11767321B2 (en) 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28103A1 (es) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
JPWO2004096806A1 (ja) * 2003-04-30 2006-07-13 大日本住友製薬株式会社 縮合イミダゾール誘導体
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
WO2005051949A1 (ja) * 2003-11-26 2005-06-09 Dainippon Sumitomo Pharma Co., Ltd. 新規縮合イミダゾール誘導体
PT1758905E (pt) * 2004-02-18 2009-07-16 Boehringer Ingelheim Int 8-[3-amino-piperidin-1-il]-xantinas, sua preparação e sua utilização como inibidores de dpp-iv
DE102004012366A1 (de) * 2004-03-13 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Imidazopyridazindione, deren Herstellung und deren Verwendung als Arzneimittel
PL1732921T3 (pl) * 2004-04-08 2009-04-30 Wyeth Corp Pochodne tioamidu jako modulatory receptora progesteronowego
EP1740589A1 (de) * 2004-04-10 2007-01-10 Boehringer Ingelheim International GmbH Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel
DE102004022970A1 (de) * 2004-05-10 2005-12-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden
DE102004038269A1 (de) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Piperidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
WO2006112331A1 (ja) * 2005-04-13 2006-10-26 Dainippon Simitomo Pharma Co., Ltd. 新規縮合ピロール誘導体
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
JP2008289437A (ja) * 2007-05-28 2008-12-04 Sony Corp レーザーを用いた酵素活性測定方法及び酵素活性測定装置
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
JP5827998B2 (ja) * 2010-09-13 2015-12-02 アドヴィナス・セラピューティックス・リミテッド Ａ２ｂアデノシン受容体アンタゴニストのプロドラッグとしてのプリン化合物、これらの方法および薬剤の適用
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2013006526A2 (en) * 2011-07-05 2013-01-10 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CN103709163B (zh) * 2012-09-29 2016-12-21 齐鲁制药有限公司 黄嘌呤衍生物、其制备方法及用途
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
EP3313841A1 (en) * 2015-06-25 2018-05-02 Boehringer Ingelheim International GmbH Process for the preparation of a xanthine-based compound
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CN108299436B (zh) * 2018-02-09 2020-01-17 上海慈瑞医药科技股份有限公司 黄嘌呤类化合物及其药物组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020161001A1 (en) * 2000-07-04 2002-10-31 Kanstrup Anders Bendtz Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US20020198205A1 (en) * 2001-02-24 2002-12-26 Frank Himmelsbach Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040082570A1 (en) * 2002-02-25 2004-04-29 Eisai Co., Ltd. Xanthine derivative and DPPIV inhibitor
US20050020574A1 (en) * 2002-12-03 2005-01-27 Boehringer Ingelheim Pharma Gmbh Co. Kg New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US122228A (en) * 1871-12-26 Improvement in head-blocks
US100199A (en) * 1870-02-22 Improvement in ditcher and grader
US219178A (en) * 1879-09-02 Improvement in steam-pressure regulators
GB8515934D0 (en) * 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
GB9906714D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
ES2294137T3 (es) * 2001-06-11 2008-04-01 Firmenich Sa Emulsion perfumante transparente y estable.
ATE388951T1 (de) 2001-07-03 2008-03-15 Novo Nordisk As Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
CN100469778C (zh) * 2002-06-06 2009-03-18 卫材R&D管理有限公司 新的稠合咪唑衍生物
US7569574B2 (en) * 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
JPWO2004028524A1 (ja) 2002-09-26 2006-01-19 エーザイ株式会社 併用医薬
EP1568699A4 (en) 2002-12-04 2007-08-15 Eisai R&D Man Co Ltd 1,3-DIHYDROIMIDAZOLE CONNECTION WITH CONDENSED RING
JPWO2004096806A1 (ja) 2003-04-30 2006-07-13 大日本住友製薬株式会社 縮合イミダゾール誘導体
US7169926B1 (en) * 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070219178A1 (en) * 2003-12-04 2007-09-20 Eisai Co., Ltd. Preventive or therapeutic agents for multiple sclerosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020161001A1 (en) * 2000-07-04 2002-10-31 Kanstrup Anders Bendtz Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US20020198205A1 (en) * 2001-02-24 2002-12-26 Frank Himmelsbach Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040082570A1 (en) * 2002-02-25 2004-04-29 Eisai Co., Ltd. Xanthine derivative and DPPIV inhibitor
US20050020574A1 (en) * 2002-12-03 2005-01-27 Boehringer Ingelheim Pharma Gmbh Co. Kg New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions

Cited By (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034014A1 (en) * 2000-07-04 2004-02-19 Kanstrup Anders Bendtz Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US7235538B2 (en) * 2000-07-04 2007-06-26 Novo Nordisk A/S Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
US20100204250A1 (en) * 2001-02-24 2010-08-12 Boehringer Ingelheim Pharma & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20060247226A1 (en) * 2001-02-24 2006-11-02 Frank Himmelsbach Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20100173916A1 (en) * 2001-02-24 2010-07-08 Boehringer Ingelheim International Gmbh Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
US20110144095A1 (en) * 2001-02-24 2011-06-16 Boehringer Ingelheim Pharma & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20110144083A1 (en) * 2001-02-24 2011-06-16 Boehringer Ingelheim International Gmbh Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions
US20040082570A1 (en) * 2002-02-25 2004-04-29 Eisai Co., Ltd. Xanthine derivative and DPPIV inhibitor
US20060100199A1 (en) * 2002-06-06 2006-05-11 Seiji Yoshikawa Novel condensed imidazole derivatives
US20090018331A1 (en) * 2002-06-06 2009-01-15 Eisai R&D Management Co., Ltd. Condensed imidazole derivatives
US7772226B2 (en) 2002-06-06 2010-08-10 Eisai R&D Management Co., Ltd. Condensed imidazole derivatives
US20060063787A1 (en) * 2002-06-06 2006-03-23 Eisai Co., Ltd. Condensed imidazole derivatives
US8178541B2 (en) 2002-08-21 2012-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20040097510A1 (en) * 2002-08-21 2004-05-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9108964B2 (en) 2002-08-21 2015-08-18 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20080255159A1 (en) * 2002-08-21 2008-10-16 Boehringer Ingelheim Pharma Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8664232B2 (en) 2002-08-21 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10023574B2 (en) 2002-08-21 2018-07-17 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10202383B2 (en) 2002-08-21 2019-02-12 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US8119648B2 (en) 2002-08-21 2012-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US7838529B2 (en) 2002-08-22 2010-11-23 Boehringer Ingelheim International Gmbh Xanthine derivates, their preparation and their use in pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US20040166125A1 (en) * 2002-08-22 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US20090131432A1 (en) * 2002-08-22 2009-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivates, their preparation and their use in pharmaceutical compositions
US20040122228A1 (en) * 2002-08-22 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) * 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20060094722A1 (en) * 2002-09-26 2006-05-04 Eisai Co., Ltd. Combination drug
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138214A1 (en) * 2002-11-08 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20100144703A1 (en) * 2002-11-08 2010-06-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7696212B2 (en) 2002-11-08 2010-04-13 Boehringer Ingelheim Pharma Gmbh And Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7560450B2 (en) 2002-11-21 2009-07-14 Boehringer Ingelheim Pharma Gmbh & Co., Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US20040138215A1 (en) * 2002-11-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7109192B2 (en) * 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
US20050020574A1 (en) * 2002-12-03 2005-01-27 Boehringer Ingelheim Pharma Gmbh Co. Kg New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
US7524847B2 (en) 2002-12-04 2009-04-28 Eisai R&D Management Co., Ltd. Fused 1,3-dihydro-imidazole ring compounds
US20060111362A1 (en) * 2002-12-04 2006-05-25 Eisai Co., Ltd. 1,3-Dihydroimidazole ring compound
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20040242566A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20040242568A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
WO2004108730A1 (en) * 2003-06-05 2004-12-16 Fujisawa Pharmaceutical Co., Ltd. 1h-imidazo`4,5-d!pyridazines as dpp-iv inhibitors for the treatment of niddm
US8034941B2 (en) 2003-06-18 2011-10-11 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
WO2004111051A1 (de) * 2003-06-18 2004-12-23 Boehringer Ingelheim International Gmbh Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel
US20090258856A1 (en) * 2003-06-18 2009-10-15 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050070535A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7723344B2 (en) 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20050070706A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7550455B2 (en) 2003-11-27 2009-06-23 Boehringer Ingelheim International Gmbh 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition
US20070219178A1 (en) * 2003-12-04 2007-09-20 Eisai Co., Ltd. Preventive or therapeutic agents for multiple sclerosis
WO2005061505A1 (en) * 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic imidazolyl pyrimidin-4-one cannabinoid receptor ligands and uses thereof
US20050171093A1 (en) * 2003-12-17 2005-08-04 Boehringer Ingelheim International Gmbh New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions
WO2005058901A1 (de) * 2003-12-17 2005-06-30 Boehringer Ingelheim International Gmbh Neue 2-(piperazin-1-yl)- und 2-([1,4]diazepan-1-yl)- imidazo[4,5-d]pyridazin-4-one, deren herstellung und deren verwendung als arzneimittel zur bekämpfung von diabetes mellitus
US7217711B2 (en) 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
US20050143377A1 (en) * 2003-12-23 2005-06-30 Boehringer Ingelheim International Gmbh Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions
US7183280B2 (en) 2003-12-23 2007-02-27 Boehringer Ingelheim International Gmbh Bicyclic imidazole derivatives, the preparation thereof and their use as pharmaceutical compositions
US20050234108A1 (en) * 2004-02-18 2005-10-20 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US8697868B2 (en) 2004-02-18 2014-04-15 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US20090137801A1 (en) * 2004-02-18 2009-05-28 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7645763B2 (en) 2004-02-23 2010-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US20050187227A1 (en) * 2004-02-23 2005-08-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050203095A1 (en) * 2004-03-13 2005-09-15 Boehringer Ingelheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7432262B2 (en) 2004-03-13 2008-10-07 Boehringer Ingelheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US20070142383A1 (en) * 2004-03-13 2007-06-21 Matthias Eckhardt Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7906523B2 (en) 2004-03-15 2011-03-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8329900B2 (en) 2004-03-15 2012-12-11 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8288539B2 (en) 2004-03-15 2012-10-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8173663B2 (en) 2004-03-15 2012-05-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7807689B2 (en) 2004-03-15 2010-10-05 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8188275B2 (en) 2004-03-15 2012-05-29 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7781584B2 (en) 2004-03-15 2010-08-24 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7476671B2 (en) 2004-04-10 2009-01-13 Boehringer Ingelheim International Gmbh 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US20090088569A1 (en) * 2004-04-10 2009-04-02 Matthias Eckhardt 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation, and their use as pharmaceutical compositions
US20070088038A1 (en) * 2004-04-10 2007-04-19 Matthias Eckhardt 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US20050261352A1 (en) * 2004-05-10 2005-11-24 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US7667035B2 (en) 2004-05-10 2010-02-23 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20080312243A1 (en) * 2004-06-24 2008-12-18 Matthias Eckhardt Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US20060004074A1 (en) * 2004-06-24 2006-01-05 Boehringer Ingelheim International Gmbh New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US7470716B2 (en) 2004-06-24 2008-12-30 Boehringer Ingelheim International Gmbh Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US7906539B2 (en) 2004-06-24 2011-03-15 Boehringer Ingelheim International Gmbh Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions
US7825242B2 (en) 2004-07-16 2010-11-02 Takeda Pharmaceutical Company Limted Dipeptidyl peptidase inhibitors
US20060058323A1 (en) * 2004-09-11 2006-03-16 Boehringer Ingelheim International Gmbh New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495003B2 (en) 2004-09-11 2009-02-24 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060079541A1 (en) * 2004-09-14 2006-04-13 Boehringer Ingelheim International Gmbh 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495002B2 (en) 2004-09-14 2009-02-24 Boehringer Ingelheim International Gmbh 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20060142310A1 (en) * 2004-11-05 2006-06-29 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US8541450B2 (en) 2004-11-05 2013-09-24 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US20090192314A1 (en) * 2004-11-05 2009-07-30 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines
US7820815B2 (en) 2004-11-05 2010-10-26 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines
US8883805B2 (en) 2004-11-05 2014-11-11 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US20090192129A1 (en) * 2004-12-12 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrrole derivatives
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20080318922A1 (en) * 2004-12-24 2008-12-25 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic Pyrrole Derivatives
US20090149483A1 (en) * 2004-12-24 2009-06-11 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrrole derivatives
US7601728B2 (en) 2004-12-24 2009-10-13 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrrole derivatives
US8198232B2 (en) 2005-01-10 2012-06-12 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US20100286153A1 (en) * 2005-01-10 2010-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
US20060154866A1 (en) * 2005-01-10 2006-07-13 Zhi-Liang Chu Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US20100298333A1 (en) * 2005-01-10 2010-11-25 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
US8003597B2 (en) 2005-01-10 2011-08-23 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US20100137293A1 (en) * 2005-01-10 2010-06-03 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
US20100285494A1 (en) * 2005-01-10 2010-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
US8022034B2 (en) 2005-01-10 2011-09-20 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US7803753B2 (en) 2005-01-10 2010-09-28 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US20100285495A1 (en) * 2005-01-10 2010-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
US7803754B2 (en) 2005-01-10 2010-09-28 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
US20100286172A1 (en) * 2005-01-10 2010-11-11 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
US8030270B2 (en) 2005-01-10 2011-10-04 Arena Pharmaceuticals, Inc. Methods for identifying GLP-1 secretagogues
US20070027168A1 (en) * 2005-07-30 2007-02-01 Waldemar Pfrengle 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8637530B2 (en) 2005-07-30 2014-01-28 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US8106060B2 (en) 2005-07-30 2012-01-31 Boehringer Ingelheim International Gmbh 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals
US20070098781A1 (en) * 2005-08-11 2007-05-03 Loeffler Bernd M Modified release compositions for DPP-IV inhibitors
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20100203577A1 (en) * 2006-04-11 2010-08-12 Arena Pharmaceuticals, Inc. Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual
US8026212B2 (en) 2006-04-11 2011-09-27 Arena Pharmaceuticals, Inc. Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgogues
US8026074B2 (en) 2006-04-11 2011-09-27 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
US7816364B2 (en) 2006-04-11 2010-10-19 Arena Pharmaceuticals, Inc. GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto
US8017574B2 (en) 2006-04-11 2011-09-13 Arena Pharmaceuticals, Inc. Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretagogues
US8580526B2 (en) 2006-04-11 2013-11-12 Arena Pharmaceuticals, Inc. Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretion
EP2253311A2 (en) 2006-04-11 2010-11-24 Arena Pharmaceuticals, Inc. Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
US20100190750A1 (en) * 2006-04-11 2010-07-29 Arena Pharmaceuticals, Inc. GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto
US8101626B2 (en) 2006-04-11 2012-01-24 Arena Pharmaceuticals, Inc. GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto
US7833730B2 (en) 2006-04-11 2010-11-16 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
US20100203037A1 (en) * 2006-04-11 2010-08-12 Arena Pharmaceuticals, Inc. Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual
US20100203038A1 (en) * 2006-04-11 2010-08-12 Arena Pharmaceuticals, Inc. Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual
US11084819B2 (en) 2006-05-04 2021-08-10 Boehringer Ingelheim International Gmbh Polymorphs
US20070281940A1 (en) * 2006-05-04 2007-12-06 Klaus Dugi Uses of dpp-iv inhibitors
US11291668B2 (en) 2006-05-04 2022-04-05 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US20080107731A1 (en) * 2006-05-04 2008-05-08 Anja Kohlrausch Dpp iv inhibitor formulations
US20110065731A1 (en) * 2006-05-04 2011-03-17 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
US8232281B2 (en) 2006-05-04 2012-07-31 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US9266888B2 (en) 2006-05-04 2016-02-23 Boehringer Ingelheim International Gmbh Polymorphs
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US9173859B2 (en) 2006-05-04 2015-11-03 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US10301313B2 (en) 2006-05-04 2019-05-28 Boehringer Ingelheim International Gmbh Polymorphs
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
US8673927B2 (en) 2006-05-04 2014-03-18 Boehringer Ingelheim International Gmbh Uses of DPP-IV inhibitors
US20070259900A1 (en) * 2006-05-04 2007-11-08 Peter Sieger Polymorphs
US11919903B2 (en) 2006-05-04 2024-03-05 Boehringer Ingelheim International Gmbh Polymorphs
US8071583B2 (en) 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2009024542A3 (en) * 2007-08-17 2009-05-22 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
WO2009024542A2 (en) * 2007-08-17 2009-02-26 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
EP3542801A1 (en) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
US20110112069A1 (en) * 2007-08-17 2011-05-12 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
EP2190434B1 (en) 2007-08-17 2019-04-17 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
AU2008290582B2 (en) * 2007-08-17 2014-08-14 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
WO2009111501A1 (en) * 2008-03-04 2009-09-11 Smithkline Beecham Corporation Derivatives of imidazo [4, 5-d] pyridazine and their use as anti-viral compounds
US20110009433A1 (en) * 2008-03-10 2011-01-13 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrrole compound
US9155705B2 (en) 2008-04-03 2015-10-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10973827B2 (en) 2008-04-03 2021-04-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US20110206766A1 (en) * 2008-04-03 2011-08-25 Boehringer Ingelheim International Gmbh Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10022379B2 (en) 2008-04-03 2018-07-17 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US8486646B2 (en) 2008-04-07 2013-07-16 Arena Pharmaceuticals, Inc. Methods of using a G protein-coupled receptor to identify peptide YY (PYY) secretagogues
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US7838254B2 (en) 2008-04-07 2010-11-23 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20100203556A1 (en) * 2008-04-07 2010-08-12 Arena Pharmaceuticals, Inc. Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy
US20100210666A1 (en) * 2008-04-07 2010-08-19 Arena Pharmaceuticals, Inc. Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy
US20110092510A1 (en) * 2008-06-03 2011-04-21 Boehringer Ingelheim International Gmbh Dpp-iv inhibitors for use in the treatment of nafld
US10034877B2 (en) 2008-08-06 2018-07-31 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US8853156B2 (en) 2008-08-06 2014-10-07 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
US9212183B2 (en) 2008-12-23 2015-12-15 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
US8846695B2 (en) 2009-01-07 2014-09-30 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
WO2011005929A1 (en) 2009-07-09 2011-01-13 Arena Pharmaceuticals, Inc. Piperidine derivative and its use for the treatment of diabets and obesity
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10092571B2 (en) 2009-11-27 2018-10-09 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011127051A1 (en) 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US9186392B2 (en) 2010-05-05 2015-11-17 Boehringer Ingelheim International Gmbh Combination therapy
US10004747B2 (en) 2010-05-05 2018-06-26 Boehringer Ingelheim International Gmbh Combination therapy
US9149478B2 (en) 2010-06-24 2015-10-06 Boehringer Ingelheim International Gmbh Diabetes therapy
WO2012040279A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2012089127A1 (en) * 2010-12-29 2012-07-05 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibitors
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9199998B2 (en) 2011-07-15 2015-12-01 Boehringer Ingelheim Internatioal Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US10195203B2 (en) 2012-05-14 2019-02-05 Boehringr Ingelheim International GmbH Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014100065A1 (en) * 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
AU2013361694B2 (en) * 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
AU2014262546B2 (en) * 2013-05-10 2018-11-08 Gilead Apollo, Llc ACC inhibitors and uses thereof
US9988399B2 (en) 2013-05-10 2018-06-05 Gilead Apollo, Llc Bicyclic compounds as ACC inhibitors and uses thereof
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
US10208063B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
US9765089B2 (en) 2013-05-10 2017-09-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
EP2994128A4 (en) * 2013-05-10 2016-11-23 Nimbus Apollo Inc ACC-HEMMER AND USES THEREOF
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
WO2016042775A1 (en) * 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US10555929B2 (en) 2015-03-09 2020-02-11 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10772865B2 (en) 2015-03-09 2020-09-15 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11400072B2 (en) 2015-03-09 2022-08-02 Coherus Biosciences, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
US11807638B2 (en) 2020-10-05 2023-11-07 Enliven Inc. 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
US11767321B2 (en) 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases

Also Published As

Publication number Publication date
JP3675813B2 (ja) 2005-07-27
CA2485641A1 (en) 2003-12-18
RU2297418C9 (ru) 2009-01-27
HK1100219A1 (en) 2007-09-14
AU2003241960B2 (en) 2009-07-30
EP1514552A1 (en) 2005-03-16
WO2003104229A1 (ja) 2003-12-18
TWI273104B (en) 2007-02-11
RU2004139111A (ru) 2005-08-10
IS7625A (is) 2005-01-04
IL165178A0 (en) 2005-12-18
MXPA04012226A (es) 2005-04-08
BR0311697A (pt) 2005-03-22
NZ536794A (en) 2007-04-27
RU2297418C2 (ru) 2007-04-20
NO20050054L (no) 2005-02-10
US20090018331A1 (en) 2009-01-15
PL374007A1 (en) 2005-09-19
TW200408639A (en) 2004-06-01
CN100469778C (zh) 2009-03-18
EP1514552A4 (en) 2008-04-02
KR20050005544A (ko) 2005-01-13
US20060100199A1 (en) 2006-05-11
KR100985160B1 (ko) 2010-10-05
US7772226B2 (en) 2010-08-10
CN1931859A (zh) 2007-03-21
ZA200500041B (en) 2006-06-01
JP2005145951A (ja) 2005-06-09
JPWO2003104229A1 (ja) 2005-10-06
HK1078869A1 (en) 2006-03-24
AU2003241960A1 (en) 2003-12-22
CN1675208A (zh) 2005-09-28
CA2485641C (en) 2010-12-14
US20060063787A1 (en) 2006-03-23
CN100348599C (zh) 2007-11-14
JP4420334B2 (ja) 2010-02-24

Similar Documents

Publication Publication Date Title
US7772226B2 (en) Condensed imidazole derivatives
KR100867485B1 (ko) 병용 의약
US20070219178A1 (en) Preventive or therapeutic agents for multiple sclerosis
US6756373B1 (en) Pharmaceutically active compounds
US8148387B2 (en) AKT and P70 S6 kinase inhibitors
US7268128B2 (en) 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action
WO2011013729A1 (ja) Ｔｔｋ阻害作用を有する縮合イミダゾール誘導体
TW201011026A (en) Therapeutic agents 414
EP1780212A1 (en) PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE

Legal Events

Date Code Title Description
AS Assignment

Owner name: EISAI CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YOSHIKAWA, SEIJI;EMORI, EITA;MATSUURA, FUMIYOSHI;AND OTHERS;REEL/FRAME:014099/0045

Effective date: 20031027

AS Assignment

Owner name: EISAI CO., LTD., JAPAN

Free format text: CORRECTION OF ASSIGNEE ADDRESS ON NOTICE OF RECORDATION FOR ASSIGNMENT RECORDED 10/31/03 AT REEL/FRAME 014099/0045;ASSIGNORS:YOSHIKAWA, SEIJI;EMORI, EITA;MATSUURA, FUMIYOSHI;AND OTHERS;REEL/FRAME:014498/0976

Effective date: 20031027

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION